pathology | treatment | patient | Demonstrated benefit and harm | k | | | |
---|
acute coronary syndrome | aspirin | not classified | versus placebo or control No demonstrated result for efficacy | 14 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
VA-pilot | aspirin vs placebo | | | Vasc events 0.23 [0.03; 1.92] Major bleeds NaN [NaN; NaN] Vasc deaths 0.31 [0.03; 2.76] Non-fatal stroke NaN [NaN; NaN] Non-fatal MI 0.00 [0.00; NaN] Non vasc deaths NaN [NaN; NaN] cardiovascular events 0.23 [0.03; 1.92] | VA-main, 1983 | aspirin vs placebo | Vasc events 0.61 [0.43; 0.88] Non-fatal MI 0.56 [0.36; 0.89] cardiovascular events 0.61 [0.43; 0.88] | | Major bleeds NaN [NaN; NaN] Vasc deaths 0.64 [0.34; 1.21] Non-fatal stroke 1.54 [0.26; 9.17] Non vasc deaths NaN [NaN; NaN] | Canadian (Aspirin + sulfinpyrazone), 1985 | aspirin + sulfinpyrazone vs placebo | | | Vasc events 0.90 [0.56; 1.45] Major bleeds NaN [NaN; NaN] Vasc deaths 0.72 [0.38; 1.35] Non-fatal stroke ∞ [NaN; ∞] Non-fatal MI 1.15 [0.50; 2.60] Non vasc deaths ∞ [NaN; ∞] cardiovascular events 0.90 [0.56; 1.45] | RISC, 1990 | aspirin vs placebo | Vasc events 0.53 [0.38; 0.74] Non-fatal MI 0.52 [0.35; 0.76] cardiovascular events 0.53 [0.38; 0.74] | | Major bleeds NaN [NaN; NaN] Vasc deaths 0.56 [0.25; 1.25] Non-fatal stroke NaN [NaN; NaN] Non vasc deaths 0.99 [0.14; 7.03] | ALDUSA-pilot | aspirin vs placebo | | | Vasc events 3.50 [0.45; 27.07] Major bleeds NaN [NaN; NaN] Vasc deaths 0.50 [0.03; 7.70] Non-fatal stroke ∞ [NaN; ∞] Non-fatal MI ∞ [NaN; ∞] Non vasc deaths NaN [NaN; NaN] cardiovascular events 3.50 [0.45; 27.07] | Théroux, 1988 | aspirin vs placebo | Non-fatal MI 0.28 [0.09; 0.82] fatal and non fatal MI 0.28 [0.09; 0.82] | | Vasc events 0.63 [0.38; 1.04] cardiovascular events 0.63 [0.38; 1.04] refractory ischemia 0.72 [0.43; 1.21] | ATACS-pilot, 1990 | aspirin vs control | | | Vasc events 0.00 [0.00; NaN] Major bleeds NaN [NaN; NaN] Vasc deaths 0.00 [0.00; NaN] Non-fatal MI 0.00 [0.00; NaN] Non vasc deaths NaN [NaN; NaN] cardiovascular events 0.00 [0.00; NaN] | Dutch-aspirin, 1990 | aspirin vs placebo | | | vascular death 0.75 [0.35; 1.62] non fatla stroke ∞ [NaN; ∞] non fatal MI 0.33 [0.07; 1.57] vascular events 0.67 [0.36; 1.23] non vascular death NaN [NaN; NaN] | ISIS-pilot, 1987 | aspirin vs placebo | | | vascular death 0.70 [0.43; 1.14] major bleeding 0.98 [0.06; 15.56] non fatla stroke 0.49 [0.04; 5.36] non fatal MI 0.76 [0.29; 2.02] vascular events 0.70 [0.46; 1.07] non vascular death NaN [NaN; NaN] | ISIS-2, 1988 | aspirin vs placebo | vascular death 0.80 [0.73; 0.87] non fatla stroke 0.56 [0.35; 0.88] non fatal MI 0.46 [0.35; 0.61] vascular events 0.74 [0.68; 0.80] | | major bleeding 1.34 [0.73; 2.46] non vascular death 0.29 [0.06; 1.38] | Huddinge, 1988 | aspirin vs control | | | vascular death NaN [NaN; NaN] non fatla stroke NaN [NaN; NaN] non fatal MI NaN [NaN; NaN] vascular events NaN [NaN; NaN] non vascular death 0.00 [0.00; NaN] | Frankfurt, 1976 | aspirin vs control | | | vascular death 1.12 [0.07; 16.98] non fatla stroke NaN [NaN; NaN] non fatal MI NaN [NaN; NaN] vascular events 1.12 [0.07; 16.98] non vascular death NaN [NaN; NaN] | APRICOT, 1993 | aspirin vs placebo | non fatal MI 0.27 [0.08; 0.94] vascular events 0.30 [0.10; 0.89] | | vascular death 0.44 [0.04; 4.82] non fatla stroke NaN [NaN; NaN] non vascular death NaN [NaN; NaN] | Canadian (Aspirin vs PBO), 1985 | aspirin vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
VA-pilot | Aspirin 324 mg/d (n=26) vs. (n=24) | | Sample size: 26/24 Primary endpoint: FU duration: 3m | VA-main, 1983 | Aspirin 324mg/d (n=661) vs. placebo (n=677) | men with unstable angina | double blind Sample size: 661/677 Primary endpoint: FU duration: 3m | Canadian (Aspirin + sulfinpyrazone), 1985 | Aspirin 1300mg/d + sulfinpyrazone 800mg/d (n=416) vs. placebo (n=139) | patients with unstable angina | double blind Sample size: 416/139 Primary endpoint: FU duration: 18m | RISC, 1990 | Aspirin 75mg/d (n=474) vs. placebo (n=471) half of the patients received heparin in a 2x2 factorial design | men with unstable coronary artery disease (unstable angina or non-Q wave myocardial infarction | double blind Factorial plan Sample size: 474/471 Primary endpoint: FU duration: 12m | ALDUSA-pilot | Aspirin 325mg/d, Aspirin 40mg/d (n=56) vs. (n=28) | | Sample size: 56/28 Primary endpoint: FU duration: 12m | Théroux, 1988 | Aspirin 325 mg twice daily (n=121) vs. placebo (n=118) | acute unstable angina | double blind Sample size: 121/118 Primary endpoint: FU duration: 6d (3m) | ATACS-pilot, 1990 | Aspirin 80mg/d (Heparin + Warfarin) (n=37) vs. full-dose heparin followed by warfarin (n=24) | acute coronary syndromes | Sample size: 37/24 Primary endpoint: FU duration: 3m | Dutch-aspirin, 1990 | aspirin (100 mg/day) for 3 months (n=50) vs. placebo (n=50) | patients with first anterior wall AMI | double blind Parallel groups Sample size: 50/50 Primary endpoint: FU duration: 3m | ISIS-pilot, 1987 | aspirin (325 mg on alternate days for 28 days) (n=313) vs. placebo (n=306) | suspected acute myocardial infarction | double blind Parallel groups Sample size: 313/306 Primary endpoint: FU duration: 1m | ISIS-2, 1988 | 160 mg/day enteric-coated aspirin for one month (n=8587) vs. placebo (n=8600) | suspected acute myocardial up to 24h | double blind Parallel groups Sample size: 8587/8600 Primary endpoint: FU duration: 35d | Huddinge, 1988 | aspirin 500mg/d starting 12 h after admissionand and then intermittently every third day for one month (n=10) vs. no aspirin (n=10) | patients with acute myocardial infarction | open Parallel groups Sample size: 10/10 Primary endpoint: FU duration: 30d (12m) | Frankfurt, 1976 | A1320 + D300, A1320 (n=25) vs. (n=28) | | Parallel groups Sample size: 25/28 Primary endpoint: FU duration: 14d | APRICOT, 1993 | 325 mg aspirin daily with discontinuation of heparin (n=107) vs. placebo (n=95) | Patients treated with intravenous thrombolytic therapy followed by intravenous heparin and with patent infarct-related artery demonstrated at angiography within 48 hours | double blind Parallel groups Sample size: 107/95 Primary endpoint: patency of the infarct related artery FU duration: 3m | Canadian (Aspirin vs PBO), 1985 | Aspirin 1300mg/d (n=-9) vs. placebo
(n=139)
| patients with unstable angina
| double blind Sample size: -9/139 Primary endpoint: FU duration: 18m
|
|
acute coronary syndrome | atopaxar | not classified | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
LANCELOT ACS | atopaxar vs placebo | | | | J-LANCELOT, 2010 | atopaxar vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
LANCELOT ACS | 400-mg loading dose of atopaxar followed by a daily dose of 50 mg, 100 mg, or 200 mg for 12 weeks (n=603) vs. placebo (n=0) | unstable-angina or non-STEMI patients | Parallel groups Sample size: 603/0 Primary endpoint: FU duration: pahse 2 | J-LANCELOT, 2010 | atopaxar at a loading dose of 400 mg followed by 50 mg per day, 100 mg per day, or 200 mg per day for 12 weeks (n=-9) vs. atopaxar at a loading dose of 400 mg followed by placebo (n=-9) | patients with acute coronary syndrome (unstable angina and NSTEMI) | Parallel groups Sample size: -9/-9 Primary endpoint: bleeding events FU duration: phase 2 study |
|
acute coronary syndrome | clopidogrel | not classified | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
COMMIT, 2005 | clopidogrel vs placebo | non fatal MI 0.82 [0.70; 0.96] vascular events 0.92 [0.87; 0.97] | | non fatla stroke 0.89 [0.70; 1.13] | | T1 vs T0 | | | |
Trial | Treatments | Patients | Method |
---|
COMMIT, 2005 | clopidogrel 75 mg daily (n=22961) vs. placebo (n=22891) | patients admitted to hospital within 24 h of suspected acute MI onset | double-blind Parallel groups Sample size: 22961/22891 Primary endpoint: death, reinfarction, or stroke FU duration: until discharge or up to 4 wee | CLARITY-TIMI 28, 2005 | clopidogrel (300-mg loading dose, followed by 75 mg once daily)
(n=-9) vs. placebo
(n=-9)
| patients, 18 to 75 years of age, within 12 hours after the onset of an ST-elevation myocardial infarction
| double blind Sample size: -9/-9 Primary endpoint: death, reMI, occlusion FU duration: 30 days
|
|
acute coronary syndrome | clopidogrel | not classified | versus aspirin No demonstrated result for efficacy clopidogrel + aspirin inferior to aspirin in terms of Major bleeds in CURE, 2001 | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
CURE, 2001 | clopidogrel + aspirin vs aspirin | Vasc events 0.82 [0.73; 0.90] fatal and non fatal MI 0.78 [0.68; 0.90] cardiovascular events 0.82 [0.73; 0.90] | Major bleeds 1.38 [1.13; 1.67] | Vasc deaths 0.93 [0.80; 1.08] Non vasc deaths 0.92 [0.60; 1.40] fatala and non fatal stroke 0.87 [0.64; 1.18] refractory ischemia 0.93 [0.83; 1.04] fatal bleeding 0.74 [0.34; 1.61] |
Trial | Treatments | Patients | Method |
---|
CURE, 2001 | clopidogrel 300 mg immediately, followed by 75 mg once daily + aspirin for 3 to 12 months (n=6259) vs. aspirin (+placebo) (n=6303) | acute coronary syndromes without ST-segment elevation within 24 hours after the onset of symptoms | double blind Parallel groups Sample size: 6259/6303 Primary endpoint: CV death, MI, stroke FU duration: NA (median <9 months) |
|
acute coronary syndrome | clopidogrel | not classified | versus clopidogrel No demonstrated result for efficacy clopidogrel high-dose regimen inferior to clopidogrel standard-dose in terms of Major bleeds in CURRENT OASIS 7 (clopidogrel), 2010 | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
CURRENT OASIS 7 (clopidogrel), 2010 | clopidogrel high-dose regimen vs clopidogrel standard-dose | | Major bleeds 1.24 [1.05; 1.46] | vascular death, MI, stroke 0.94 [0.83; 1.06] Severe recurrent ischemia 0.93 [0.64; 1.36] Hemorrhagic stoke 0.67 [0.19; 2.37] Vasc events 0.94 [0.84; 1.06] all cause death 0.96 [0.82; 1.13] Vasc deaths 0.95 [0.81; 1.13] fatala and non fatal stroke 0.99 [0.70; 1.39] fatal and non fatal MI 0.86 [0.72; 1.02] cardiovascular events 0.94 [0.84; 1.06] fatal bleeding 1.07 [0.53; 2.16] |
Trial | Treatments | Patients | Method |
---|
CURRENT OASIS 7 (clopidogrel), 2010 | Double-dose clopidogrel (n=12520) vs. Standard-dose clopidogrel (n=12566) patients were also assigned in an open-label manner to 300 to 325 mg of aspirin once daily or 75- to 100-mg aspirin once daily | ACS patients referred for an invasive strategy (scheduled for percutaneous coronary intervention no more than 72 hours after randomization) about two thirds eventually underwent PCI (although PCI was planned for everyone who was randomized, about a third of the patients did not undergo the procedure because they were not considered suitable based on angiography findings) | open Factorial plan Sample size: 12520/12566 Primary endpoint: CV death/MI/stroke FU duration: 30 days |
|
acute coronary syndrome | dipyridamol | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Prandoni, 1991 | aspirin + dipyridamol vs placebo | | | Vasc events 0.55 [0.22; 1.35] Major bleeds NaN [NaN; NaN] Vasc deaths ∞ [NaN; ∞] Non-fatal stroke NaN [NaN; NaN] Non-fatal MI 0.45 [0.17; 1.20] Non vasc deaths ∞ [NaN; ∞] cardiovascular events 0.55 [0.22; 1.35] |
Trial | Treatments | Patients | Method |
---|
Prandoni, 1991 | Aspirin 50mg/d + Dipyridamol 400mg/d (n=44) vs. placebo (n=44) | patients with acute unstable angina | double blind Sample size: 44/44 Primary endpoint: FU duration: 12m |
|
acute coronary syndrome | elinogrel | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
ERASE-MI, 2009 | elinogrel vs placebo | | | major bleeding NaN [NaN; NaN] non fatla stroke ∞ [NaN; ∞] non fatal MI NaN [NaN; NaN] |
Trial | Treatments | Patients | Method |
---|
ERASE-MI, 2009 | elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus (n=34) vs. placebo (n=36) 5 arms: 4 doses of elinogrel or placebo before the start of the diagnostic angiogram preceding primary PCI | STEMI patients | double blind Parallel groups Sample size: 34/36 Primary endpoint: TIMI and ST resolution FU duration: 30-37 days phase IIb (dose-escalation study) |
|
acute coronary syndrome | prasugrel | not classified | versus clopidogrel No demonstrated result for efficacy prasugrel inferior to clopidogrel in terms of all bleeding (major and minor) in TRITON-TIMI 38, 2007 prasugrel inferior to clopidogrel in terms of Major bleeds in TRITON-TIMI 38, 2007 prasugrel inferior to clopidogrel in terms of fatal bleeding in TRITON-TIMI 38, 2007 | 2 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
TRILOGY ACS (overall population), 2012 | prasugrel vs clopidogrel | | | all cause death 0.94 [0.82; 1.08] all bleeding (major and minor) 1.26 [0.94; 1.69] Major bleeds 1.21 [0.83; 1.77] Vasc deaths 0.93 [0.80; 1.08] fatala and non fatal stroke 0.90 [0.64; 1.26] fatal and non fatal MI 0.96 [0.84; 1.10] fatal bleeding 0.78 [0.29; 2.09] death, MI, stroke 0.96 [0.87; 1.06] | TRITON-TIMI 38, 2007 | prasugrel vs clopidogrel | Vasc events 0.82 [0.74; 0.91] revascularization 0.67 [0.55; 0.82] Non-fatal MI 0.76 [0.68; 0.86] | all bleeding (major and minor) 1.31 [1.11; 1.55] Major bleeds 1.31 [1.03; 1.68] fatal bleeding 4.19 [1.58; 11.10] | all cause death 0.95 [0.78; 1.16] Vasc deaths 0.88 [0.70; 1.11] Non-fatal stroke 1.01 [0.71; 1.45] |
Trial | Treatments | Patients | Method |
---|
TRILOGY ACS (overall population), 2012 | prasugrel 10 mg daily (n=4663) vs. clopidogrel 75 mg daily (n=4663) | patients with acute coronary syndromes selected for a final treatment
strategy of medical management without revascularization
within 10 days after the index event | double-blind Parallel groups Sample size: 4663/4663 Primary endpoint: cardiovascular events FU duration: 17 months (median) | TRITON-TIMI 38, 2007 | prasugrel 60-mg loading dose
and 10-mg daily maintenance dose, for 6 to 15 months (n=6813) vs. clopidogrel (a 300-mg loading dose and a
75-mg daily maintenance dose) for 6 to 15 months (n=6795) | patients with moderate-to-high-risk acute coronary syndromes (UA, NSTEMI,STEMI) with scheduled
percutaneous coronary intervention | double blind Parallel groups Sample size: 6813/6795 Primary endpoint: cardiovascular death, nonfatal MI, or nonfatal FU duration: |
|
acute coronary syndrome | sulfinpyrazone | not classified | versus placebo or control No demonstrated result for efficacy | 4 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Dutch sulphinpyrazone, 1986 | sulfinpyrazone vs control | | | vascular death 0.50 [0.10; 2.61] major bleeding NaN [NaN; NaN] non fatla stroke NaN [NaN; NaN] non fatal MI NaN [NaN; NaN] vascular events 0.50 [0.10; 2.61] non vascular death NaN [NaN; NaN] | Wilcox, 1980 | sulfinpyrazone vs placebo | | | vascular death 5.00 [0.61; 41.25] vascular events 5.00 [0.61; 41.25] non vascular death NaN [NaN; NaN] | Louvain sulphinpyrazone, 1983 | sulfinpyrazone vs placebo | | | vascular death ∞ [NaN; ∞] vascular events ∞ [NaN; ∞] non vascular death NaN [NaN; NaN] | Canadian (sulfinpyrazone alone), 1985 | sulfinpyrazone vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
Dutch sulphinpyrazone, 1986 | S (W) (n=50) vs. (n=50) | | Parallel groups Sample size: 50/50 Primary endpoint: FU duration: 21d | Wilcox, 1980 | Sulphinpyrazone 200 mg four times daily (n=49) vs. placebo (n=49) | patients with acute myocardial infarction | Parallel groups Sample size: 49/49 Primary endpoint: FU duration: 10d | Louvain sulphinpyrazone, 1983 | sulphinpyrazone, 4 x 200 mg daily for 7 days (n=15) vs. placebo (n=14) | recent myocardial infarction | double blind Parallel groups Sample size: 15/14 Primary endpoint: renal function FU duration: 7d | Canadian (sulfinpyrazone alone), 1985 | sulfinpyrazone 800mg/d
(n=-9) vs. placebo
(n=139)
| patients with unstable angina
| double blind Sample size: -9/139 Primary endpoint: FU duration: 18m
|
|
acute coronary syndrome | ticagrelor | not classified | versus clopidogrel No demonstrated result for efficacy | 2 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
PLATO, 2009 | ticagrelor vs clopidogrel | vascular death, MI, stroke 0.85 [0.78; 0.92] Vasc events 0.88 [0.82; 0.95] all cause death 0.78 [0.69; 0.89] Vasc deaths 0.80 [0.69; 0.91] fatal and non fatal MI 0.85 [0.75; 0.95] cardiovascular events 0.85 [0.78; 0.92] death, MI, stroke 0.84 [0.77; 0.92] | | Severe recurrent ischemia 0.87 [0.75; 1.01] Hemorrhagic stoke 1.76 [0.89; 3.47] all bleeding (major and minor) 1.04 [0.95; 1.13] Major bleeds 1.03 [0.92; 1.14] Ischemic stroke 1.05 [0.79; 1.40] Non vasc deaths 0.72 [0.49; 1.04] fatala and non fatal stroke 1.17 [0.91; 1.52] fatal bleeding 0.87 [0.48; 1.58] | DISPERSE-2 (90mg), 2007 | ticagrelor vs clopidogrel | | | Vasc events 1.09 [0.58; 2.07] all cause death 1.37 [0.44; 4.27] all bleeding (major and minor) 1.11 [0.70; 1.77] Major bleeds 0.98 [0.58; 1.65] Vasc deaths 1.47 [0.42; 5.16] fatala and non fatal stroke 1.96 [0.18; 21.49] fatal and non fatal MI 0.78 [0.37; 1.65] cardiovascular events 1.09 [0.58; 2.07] |
Trial | Treatments | Patients | Method |
---|
PLATO, 2009 | ticagrelor 90mg twice daily (n=9333) vs. clopidogrel 75mg once daily (n=9291) Patients undergoing PCI after randomization received,
in a blind fashion, an additional dose of
their study drug at the time of PCI | patients with an acute coronary syndrome, with or without
ST-segment elevation (onset
of symptoms within the previous 24h). | double blind Parallel groups Sample size: 9333/9291 Primary endpoint: Cv death, MI, stroke FU duration: 1 y | DISPERSE-2 (90mg), 2007 | ticagrelor 90 mg twice daily (n=334) vs. clopidogrel (n=327) 3 arms trial: AZD6140 90 mg and 180mg twice daily, Clopidogrel 75 mg
daily | patients with NSTE-ACS, treated with aspirin and standard therapy for ACS | double blind Parallel groups Sample size: 334/327 Primary endpoint: major or minor bleeding through 4 weeks FU duration: 12 weeks |
|
acute coronary syndrome | ticlopidine | not classified | versus placebo or control No demonstrated result for efficacy | 3 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
STAI, 1990 | ticlopidine vs control | Vasc events 0.52 [0.32; 0.83] Non-fatal MI 0.54 [0.30; 0.98] cardiovascular events 0.52 [0.32; 0.83] | | Major bleeds NaN [NaN; NaN] Vasc deaths 0.54 [0.23; 1.24] Non-fatal stroke 0.00 [0.00; NaN] Non vasc deaths NaN [NaN; NaN] | Florida UA | ticlopidine vs placebo | | | Vasc events 1.00 [0.17; 5.98] Major bleeds NaN [NaN; NaN] Vasc deaths NaN [NaN; NaN] Non-fatal stroke NaN [NaN; NaN] Non-fatal MI 1.00 [0.17; 5.98] Non vasc deaths NaN [NaN; NaN] cardiovascular events 1.00 [0.17; 5.98] | Knudsen-A, 1985 | ticlopidine vs control | | | vascular death NaN [NaN; NaN] non fatla stroke NaN [NaN; NaN] non fatal MI NaN [NaN; NaN] vascular events NaN [NaN; NaN] non vascular death NaN [NaN; NaN] |
Trial | Treatments | Patients | Method |
---|
STAI, 1990 | ticlopidine 250 mg b.i.d (n=314) vs. untreated control (n=338) | patients with unstable angina <=48hrs from the pain onset | single blind Sample size: 314/338 Primary endpoint: FU duration: 6m | Florida UA | Ticlopidine 500mg/d (n=12) vs. (n=12) | | Sample size: 12/12 Primary endpoint: FU duration: 14d | Knudsen-A, 1985 | ticlopidine 500mg/d (n=24) vs. placebo (n=19) | patients with AMI | double blind Parallel groups Sample size: 24/19 Primary endpoint: FU duration: 3m |
|
acute coronary syndrome | trapidil | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Modena | trapidil vs placebo | Vasc events 0.21 [0.05; 0.91] cardiovascular events 0.21 [0.05; 0.91] | | Vasc deaths 0.21 [0.02; 1.72] Non-fatal MI 0.21 [0.02; 1.72] |
Trial | Treatments | Patients | Method |
---|
Modena | trapidil (n=71) vs. (n=73) | | Sample size: 71/73 Primary endpoint: FU duration: 6m |
|
acute coronary syndrome | triflusal | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Plaza, 1993 | triflusal vs placebo | Non-fatal MI 0.34 [0.14; 0.84] | | Vasc events 0.45 [0.20; 1.02] revascularization 0.83 [0.51; 1.35] Major bleeds NaN [NaN; NaN] Vasc deaths ∞ [NaN; ∞] Non vasc deaths NaN [NaN; NaN] cardiovascular events 0.45 [0.20; 1.02] |
Trial | Treatments | Patients | Method |
---|
Plaza, 1993 | triflusal 300 mg three times daily (n=143) vs. placebo (n=138) | patients with unstable angina | double blind Parallel groups Sample size: 143/138 Primary endpoint: FU duration: 6m |
|
acute coronary syndrome | vorapaxar | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
TRACER, 2011 | vorapaxar vs placebo (on top standard therapy) | | | |
Trial | Treatments | Patients | Method |
---|
TRACER, 2011 | vorapaxar (SCH 530348) oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year
(n=-9) vs. Placebo (added to the existing standard of care (eg, aspirin, clopidogrel) (n=-9) | patients with acute coronary syndrome | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: CV death, MI, stroke, recurrent ischaemia, urgent revasc FU duration: |
|
acute myocardial infarction | aspirin | not classified | versus placebo or control No demonstrated result for efficacy | 6 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Dutch-aspirin, 1990 | aspirin vs placebo | | | vascular death 0.75 [0.35; 1.62] non fatla stroke ∞ [NaN; ∞] non fatal MI 0.33 [0.07; 1.57] vascular events 0.67 [0.36; 1.23] non vascular death NaN [NaN; NaN] | ISIS-pilot, 1987 | aspirin vs placebo | | | vascular death 0.70 [0.43; 1.14] major bleeding 0.98 [0.06; 15.56] non fatla stroke 0.49 [0.04; 5.36] non fatal MI 0.76 [0.29; 2.02] vascular events 0.70 [0.46; 1.07] non vascular death NaN [NaN; NaN] | ISIS-2, 1988 | aspirin vs placebo | vascular death 0.80 [0.73; 0.87] non fatla stroke 0.56 [0.35; 0.88] non fatal MI 0.46 [0.35; 0.61] vascular events 0.74 [0.68; 0.80] | | major bleeding 1.34 [0.73; 2.46] non vascular death 0.29 [0.06; 1.38] | Huddinge, 1988 | aspirin vs control | | | vascular death NaN [NaN; NaN] non fatla stroke NaN [NaN; NaN] non fatal MI NaN [NaN; NaN] vascular events NaN [NaN; NaN] non vascular death 0.00 [0.00; NaN] | Frankfurt, 1976 | aspirin vs control | | | vascular death 1.12 [0.07; 16.98] non fatla stroke NaN [NaN; NaN] non fatal MI NaN [NaN; NaN] vascular events 1.12 [0.07; 16.98] non vascular death NaN [NaN; NaN] | APRICOT, 1993 | aspirin vs placebo | non fatal MI 0.27 [0.08; 0.94] vascular events 0.30 [0.10; 0.89] | | vascular death 0.44 [0.04; 4.82] non fatla stroke NaN [NaN; NaN] non vascular death NaN [NaN; NaN] |
Trial | Treatments | Patients | Method |
---|
Dutch-aspirin, 1990 | aspirin (100 mg/day) for 3 months (n=50) vs. placebo (n=50) | patients with first anterior wall AMI | double blind Parallel groups Sample size: 50/50 Primary endpoint: FU duration: 3m | ISIS-pilot, 1987 | aspirin (325 mg on alternate days for 28 days) (n=313) vs. placebo (n=306) | suspected acute myocardial infarction | double blind Parallel groups Sample size: 313/306 Primary endpoint: FU duration: 1m | ISIS-2, 1988 | 160 mg/day enteric-coated aspirin for one month (n=8587) vs. placebo (n=8600) | suspected acute myocardial up to 24h | double blind Parallel groups Sample size: 8587/8600 Primary endpoint: FU duration: 35d | Huddinge, 1988 | aspirin 500mg/d starting 12 h after admissionand and then intermittently every third day for one month (n=10) vs. no aspirin (n=10) | patients with acute myocardial infarction | open Parallel groups Sample size: 10/10 Primary endpoint: FU duration: 30d (12m) | Frankfurt, 1976 | A1320 + D300, A1320 (n=25) vs. (n=28) | | Parallel groups Sample size: 25/28 Primary endpoint: FU duration: 14d | APRICOT, 1993 | 325 mg aspirin daily with discontinuation of heparin (n=107) vs. placebo (n=95) | Patients treated with intravenous thrombolytic therapy followed by intravenous heparin and with patent infarct-related artery demonstrated at angiography within 48 hours | double blind Parallel groups Sample size: 107/95 Primary endpoint: patency of the infarct related artery FU duration: 3m |
|
acute myocardial infarction | clopidogrel | not classified | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
COMMIT, 2005 | clopidogrel vs placebo | non fatal MI 0.82 [0.70; 0.96] vascular events 0.92 [0.87; 0.97] | | non fatla stroke 0.89 [0.70; 1.13] | | T1 vs T0 | | | |
Trial | Treatments | Patients | Method |
---|
COMMIT, 2005 | clopidogrel 75 mg daily (n=22961) vs. placebo (n=22891) | patients admitted to hospital within 24 h of suspected acute MI onset | double-blind Parallel groups Sample size: 22961/22891 Primary endpoint: death, reinfarction, or stroke FU duration: until discharge or up to 4 wee | CLARITY-TIMI 28, 2005 | clopidogrel (300-mg loading dose, followed by 75 mg once daily)
(n=-9) vs. placebo
(n=-9)
| patients, 18 to 75 years of age, within 12 hours after the onset of an ST-elevation myocardial infarction
| double blind Sample size: -9/-9 Primary endpoint: death, reMI, occlusion FU duration: 30 days
|
|
acute myocardial infarction | elinogrel | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
ERASE-MI, 2009 | elinogrel vs placebo | | | major bleeding NaN [NaN; NaN] non fatla stroke ∞ [NaN; ∞] non fatal MI NaN [NaN; NaN] |
Trial | Treatments | Patients | Method |
---|
ERASE-MI, 2009 | elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus (n=34) vs. placebo (n=36) 5 arms: 4 doses of elinogrel or placebo before the start of the diagnostic angiogram preceding primary PCI | STEMI patients | double blind Parallel groups Sample size: 34/36 Primary endpoint: TIMI and ST resolution FU duration: 30-37 days phase IIb (dose-escalation study) |
|
acute myocardial infarction | sulfinpyrazone | not classified | versus placebo or control No demonstrated result for efficacy | 3 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Dutch sulphinpyrazone, 1986 | sulfinpyrazone vs control | | | vascular death 0.50 [0.10; 2.61] major bleeding NaN [NaN; NaN] non fatla stroke NaN [NaN; NaN] non fatal MI NaN [NaN; NaN] vascular events 0.50 [0.10; 2.61] non vascular death NaN [NaN; NaN] | Wilcox, 1980 | sulfinpyrazone vs placebo | | | vascular death 5.00 [0.61; 41.25] vascular events 5.00 [0.61; 41.25] non vascular death NaN [NaN; NaN] | Louvain sulphinpyrazone, 1983 | sulfinpyrazone vs placebo | | | vascular death ∞ [NaN; ∞] vascular events ∞ [NaN; ∞] non vascular death NaN [NaN; NaN] |
Trial | Treatments | Patients | Method |
---|
Dutch sulphinpyrazone, 1986 | S (W) (n=50) vs. (n=50) | | Parallel groups Sample size: 50/50 Primary endpoint: FU duration: 21d | Wilcox, 1980 | Sulphinpyrazone 200 mg four times daily (n=49) vs. placebo (n=49) | patients with acute myocardial infarction | Parallel groups Sample size: 49/49 Primary endpoint: FU duration: 10d | Louvain sulphinpyrazone, 1983 | sulphinpyrazone, 4 x 200 mg daily for 7 days (n=15) vs. placebo (n=14) | recent myocardial infarction | double blind Parallel groups Sample size: 15/14 Primary endpoint: renal function FU duration: 7d |
|
acute myocardial infarction | ticlopidine | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Knudsen-A, 1985 | ticlopidine vs control | | | vascular death NaN [NaN; NaN] non fatla stroke NaN [NaN; NaN] non fatal MI NaN [NaN; NaN] vascular events NaN [NaN; NaN] non vascular death NaN [NaN; NaN] |
Trial | Treatments | Patients | Method |
---|
Knudsen-A, 1985 | ticlopidine 500mg/d (n=24) vs. placebo (n=19) | patients with AMI | double blind Parallel groups Sample size: 24/19 Primary endpoint: FU duration: 3m |
|
CABG surgery | aspirin | not classified | versus placebo or control No demonstrated result for efficacy | 5 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
McEnany, 1982 | aspirin vs placebo | | | vascular death 0.36 [0.04; 3.40] Non fatal stroke NaN [NaN; NaN] non fatal MI 0.00 [0.00; NaN] non vascular death NaN [NaN; NaN] vascular event 0.22 [0.03; 1.81] | Lorenz, 1984 | aspirin vs placebo | | | vascular death 1.07 [0.16; 7.10] Non fatal stroke 0.00 [0.00; NaN] non fatal MI 0.00 [0.00; NaN] non vascular death NaN [NaN; NaN] vascular event 0.53 [0.11; 2.70] | GESIC (aspirin), 1990 | aspirin vs placebo | | | vascular death 2.59 [0.93; 7.18] non vascular death NaN [NaN; NaN] vascular event 2.59 [0.93; 7.18] | | aspirin vs placebo | | | | | aspirin vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
McEnany, 1982 | aspirin 1200 (n=71) vs. placebo (n=77) | patients undergoing coronary bypass grafting | double blind Sample size: 71/77 Primary endpoint: FU duration: 22m | Lorenz, 1984 | aspirin 100 mg/d (n=29) vs. placebo (n=31) | patients undergoing CABG | double blind Sample size: 29/31 Primary endpoint: FU duration: 4m | GESIC (aspirin), 1990 | aspirin 150 mg daily (n=373) vs. placebo (n=371) 3 arms trials: placebo, aspirin, aspirin + dipyridamole | patients undergoing CABG | double blind Parallel groups Sample size: 373/371 Primary endpoint: FU duration: 28d | Sydney, 1991 | aspirin 324 mg daily (n=127) vs. placebo (n=110) | patients undergoing CABG | double blind Sample size: 127/110 Primary endpoint: FU duration: 12m | Hockings, 1993 | aspirin 100 (n=72) vs. placebo (n=72) | patients undergoing CABG | double blind Sample size: 72/72 Primary endpoint: FU duration: 6m |
|
CABG surgery | clopidogrel | not classified | versus No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
CASCADE, 2009 | clopidogrel+aspirin vs aspirin | | | |
Trial | Treatments | Patients | Method |
---|
CASCADE, 2009 | aspirin 162 mg plus clopidogrel 75 mg daily for 1 year (n=56) vs. aspirin 162 mg plus placebo daily (n=57) | patients after CABG involving at least two saphenous vein grafts | double blind Parallel groups Sample size: 56/57 Primary endpoint: vein graft intimal area FU duration: 1 y |
|
CABG surgery | dipyridamol | not classified | versus No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
GESIC (aspirin+dipyridamol), 1990 | aspirin + dipyridamol vs placebo | | | vascular death 1.81 [0.61; 5.36] vascular event 1.81 [0.61; 5.36] |
Trial | Treatments | Patients | Method |
---|
GESIC (aspirin+dipyridamol), 1990 | aspirin 50 mg + dipyridamole 75mg 3 times daily
(n=368) vs. placebo
(n=371) 3 arms trials: placebo, aspirin, aspirin + dipyridamole
| patients undergoing CABG
| double blind Parallel groups Sample size: 368/371 Primary endpoint: FU duration: 28d
|
|
CABG surgery | dipyridamol | not classified | versus placebo or control No demonstrated result for efficacy | 12 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Brooks, 1985 | aspirin + dipyridamol vs placebo | | | vascular death 2.00 [0.61; 6.51] non vascular death NaN [NaN; NaN] vascular event 2.00 [0.61; 6.51] | Mayo-A, 1984 | aspirin + dipyridamol vs placebo | | | vascular death 0.85 [0.26; 2.73] vascular event 0.85 [0.26; 2.73] | Pantely, 1979 | aspirin + dipyridamol vs control | | | vascular death NaN [NaN; NaN] Non fatal stroke NaN [NaN; NaN] non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event NaN [NaN; NaN] | Wadsworth, 1985 | aspirin + dipyridamol vs placebo | | | vascular death 2.13 [0.20; 23.06] Non fatal stroke 1.06 [0.07; 16.75] non vascular death NaN [NaN; NaN] vascular event 1.59 [0.27; 9.33] | Brussels, 1987 | aspirin + dipyridamol vs control | | | vascular death ∞ [NaN; ∞] Non fatal stroke 0.00 [0.00; NaN] non fatal MI 0.52 [0.05; 5.38] non vascular death NaN [NaN; NaN] vascular event 0.69 [0.13; 3.80] | Basel, 1989 | aspirin + dipyridamol vs placebo | | | vascular death NaN [NaN; NaN] non fatal MI 0.00 [0.00; NaN] non vascular death NaN [NaN; NaN] vascular event 0.00 [0.00; NaN] | | aspirin + dipyridamol vs placebo | | | | | aspirin + dipyridamol vs control | | | | | aspirin + dipyridamol vs placebo | | | | | aspirin + dipyridamol vs control | | | | | dipyridamol vs control | | | | | dipyridamol vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
Brooks, 1985 | aspirin 990 mg and dipyridamole 225 mg daily (n=160) vs. placebo (n=160) | patients undergoing coronary bypass grafting | double blind Sample size: 160/160 Primary endpoint: FU duration: 12m | Mayo-A, 1984 | aspirin 975 + dipiridamol 225 (n=202) vs. placebo (n=205) | patients undergoing coronary bypass grafting | double blind Sample size: 202/205 Primary endpoint: FU duration: 12m | Pantely, 1979 | aspirin 325 mg three times a day + dipyridamole 75 mg three times a day (n=18) vs. control (n=30) | patients undergoing aortocoronary saphenous-vein bypass-graft surgery | open Sample size: 18/30 Primary endpoint: FU duration: 6m | Wadsworth, 1985 | aspirin 975 mg/d + dipiridamol 225 mg/d, aspirin 975 mg/d (n=96) vs. placebo (n=102) | coronary bypass patients | double blind Sample size: 96/102 Primary endpoint: FU duration: 12m | Brussels, 1987 | aspirin 200 + dipiridamol 400 (H) (n=24) vs. (n=25) | | Sample size: 24/25 Primary endpoint: FU duration: 12m | Basel, 1989 | aspirin 50 + dipiridamol 400 (n=62) vs. placebo (n=63) | patients who had aortocoronary vein bypass surgery | double blind Sample size: 62/63 Primary endpoint: FU duration: 9m | Leeds-B, 1985 | aspirin 990 + dipiridamol 225 (W) (n=61) vs. placebo (n=64) | patients undergoing aorta-coronary bypass grafting for disabling angina | double blind Sample size: 61/64 Primary endpoint: FU duration: 6m | Czech, 1986 | aspirin 1000 + dipiridamol 225 (n=47) vs. control (no medication) (n=46) | Patients with aortocoronary bypasses with intraoperative blood flow rates of 40 ml/min or less | open Sample size: 47/46 Primary endpoint: FU duration: 12m | Thaulow, 1987 | aspirin 975 + dipiridamol 225 (n=34) vs. placebo (n=35) | Patients scheduled to receive at least three aortocoronary venous bypass grafts | double blind Sample size: 34/35 Primary endpoint: FU duration: 3m | Des Moines, 1980 | aspirin 20 + dipiridamol 100 (n=60) vs. (n=54) | | Sample size: 60/54 Primary endpoint: FU duration: 12m | Toronto dipyridamole, 1987 | dipiridamol 400 (n=20) vs. control (n=20) | patients undergoing elective coronary artery bypass grafting | Sample size: 20/20 Primary endpoint: FU duration: 48h | Ekestrom, 1990 | dipiridamol 100 mg orally q.i.d. (n=174) vs. placebo (n=186) | patients undergoing coronary bypass surgery | double blind Sample size: 174/186 Primary endpoint: FU duration: 12m |
|
CABG surgery | sulfinpyrazone | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| sulfinpyrazone vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
Baur, 1982 | sulfinpyrazone 800 mg/day (n=130) vs. placebo (n=125) | patients undergoing CABG | double blind Sample size: 130/125 Primary endpoint: FU duration: 10d |
|
CABG surgery | sulotroban | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| sulotroban vs control | | | |
Trial | Treatments | Patients | Method |
---|
German sulotroban, 1989 | ST (n=90) vs. (n=85) | | Sample size: 90/85 Primary endpoint: FU duration: 21d |
|
CABG surgery | ticlopidine | not classified | versus placebo or control No demonstrated result for efficacy | 6 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Liège-I, 1984 | ticlopidine vs placebo | | | vascular death 0.00 [0.00; NaN] Non fatal stroke 0.00 [0.00; NaN] non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event 0.00 [0.00; NaN] | Liège-II, 1987 | ticlopidine vs placebo | | | vascular death 1.98 [0.18; 21.41] Non fatal stroke 0.00 [0.00; NaN] non fatal MI 0.33 [0.03; 3.11] non vascular death 0.00 [0.00; NaN] vascular event 0.49 [0.13; 1.91] | | ticlopidine vs control | | | | | ticlopidine vs control | | | | | ticlopidine vs control | | | | | ticlopidine vs control | | | |
Trial | Treatments | Patients | Method |
---|
Liège-I, 1984 | ticlopidine 250 mg twice daily (n=75) vs. placebo (n=75) | patients undergoing aortocoronary bypass graft procedures | double blind Sample size: 75/75 Primary endpoint: FU duration: 3m | Liège-II, 1987 | ticlopidine 250 mg twice daily (n=88) vs. placebo (n=87) | patients undergoing venous coronary artery bypass grafting | double blind Sample size: 88/87 Primary endpoint: FU duration: 12m | Zurich, 1982 | ticlopidine 500 (NC) (n=50) vs. (n=50) | | Sample size: 50/50 Primary endpoint: FU duration: 3m | Knudsen-B, 1983 | ticlopidine 500 (n=9) vs. (n=10) | | Sample size: 9/10 Primary endpoint: FU duration: 6m | Romeo, 1983 | ticlopidine 500 (n=20) vs. (n=20) | | Sample size: 20/20 Primary endpoint: FU duration: 3m (12m) | Kohn, 1990 | ticlopidine 500 (n=21) vs. (n=24) | | Sample size: 21/24 Primary endpoint: FU duration: 14d |
|
cardiovascular prevention | aspirin | not classified | versus No demonstrated result for efficacy aspirin inferior to placebo in terms of major bleeding in ASCEND, 2018 | 2 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
ASPREE, 2018 | aspirin vs placebo | | | | ASCEND, 2018 | aspirin vs placebo | Cv death 0.88 [0.79; 0.98] CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.88 [0.79; 0.98] | major bleeding 1.29 [1.09; 1.52] | |
Trial | Treatments | Patients | Method |
---|
ASPREE, 2018 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | ASCEND, 2018 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
|
cardiovascular prevention | aspirin | not classified | versus placebo or control No demonstrated result for efficacy aspirin inferior to placebo in terms of non fatal MI in DAMAD, 1989 | 21 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
CDPA, 1976 | aspirin vs placebo | | | Total mortality 0.70 [0.48; 1.01] Cardiovascular death 0.70 [0.47; 1.02] Non-fatal MI 0.89 [0.54; 1.46] | Cardiff I, 1974 | aspirin vs placebo | | | Total mortality 0.74 [0.52; 1.05] | Cardiff II, 1979 | aspirin vs placebo | | | Total mortality 0.83 [0.65; 1.05] | Vogel, 1979 | aspirin vs placebo | Cardiovascular death 0.50 [0.27; 0.92] Fatal MI 0.38 [0.17; 0.85] Non-fatal MI 0.47 [0.29; 0.75] | | Total mortality 0.68 [0.44; 1.05] | AMIS, 1980 | aspirin vs placebo | Non-fatal MI 0.78 [0.63; 0.96] | | Total mortality 1.11 [0.94; 1.32] | GAMIS, 1980 | aspirin vs placebo | | | Total mortality 0.82 [0.51; 1.34] Fatal MI 0.49 [0.17; 1.41] Non-fatal MI 0.71 [0.33; 1.53] | PARIS, 1980 | aspirin vs placebo | | | Total mortality 0.82 [0.59; 1.13] Cardiovascular death 0.82 [0.58; 1.17] Non-fatal MI 0.70 [0.48; 1.03] | JAMIS, 1999 | aspirin vs placebo | Non-fatal MI 0.27 [0.10; 0.72] | | Total mortality 1.18 [0.45; 3.12] Cardiovascular death 1.10 [0.34; 3.57] | | aspirin vs placebo | | | | | aspirin vs placebo | | | | | aspirin vs placebo | | | | | aspirin vs placebo | | | | SAPAT, 1992 | aspirin vs placebo | Non fatal MI 0.67 [0.45; 0.98] vascular event 0.71 [0.57; 0.89] | | vascular death 0.76 [0.54; 1.07] Non fatal stroke 0.79 [0.45; 1.39] non vascular death 1.66 [0.79; 3.51] | POPADAD aspirin, 2008 | aspirin vs placebo | | | All cause mortality 0.93 [0.72; 1.21] CHD death 1.35 [0.82; 2.21] CHD events (fatal and non fatal) 1.10 [0.83; 1.45] CV death 1.23 [0.80; 1.89] fatal MI 1.35 [0.82; 2.21] fatal stroke 0.89 [0.35; 2.29] non fatal MI 0.98 [0.69; 1.40] stroke (fatal and non fatal) 0.74 [0.49; 1.12] CV events (fatal and non fatal) 0.99 [0.79; 1.25] peripheral artery disease 0.91 [0.70; 1.17] stable angina 0.90 [0.66; 1.22] | JPAD, 2008 | aspirin vs no treatment | CV death 0.10 [0.01; 0.79] | | CHD death 0.00 [0.00; NaN] CHD events (fatal and non fatal) 0.81 [0.50; 1.32] fatal MI 0.00 [0.00; NaN] fatal stroke 0.20 [0.02; 1.73] non fatal MI 1.35 [0.57; 3.19] stroke (fatal and non fatal) 0.89 [0.54; 1.46] CV events (fatal and non fatal) 0.80 [0.59; 1.09] peripheral artery disease 0.64 [0.25; 1.66] stable angina 1.10 [0.49; 2.49] unstable angina 0.40 [0.13; 1.29] | DAMAD, 1989 | aspirin vs placebo | | non fatal MI 4.20 [1.10; 16.10] | All cause mortality 0.49 [0.13; 1.95] CV death 0.49 [0.10; 2.42] CV events (fatal and non fatal) 1.48 [0.68; 3.22] | ETDRS, 1992 | aspirin vs placebo | CHD events (fatal and non fatal) 0.85 [0.73; 1.00] | | All cause mortality 0.93 [0.81; 1.06] CV death 0.92 [0.79; 1.07] non fatal MI 0.78 [0.54; 1.11] stroke (fatal and non fatal) 1.18 [0.88; 1.58] CV events (fatal and non fatal) 0.95 [0.83; 1.07] | CLIPS, 2007 | aspirin vs placebo | Evénements vasculaires 0.42 [0.22; 0.80] IDM totaux 0.18 [0.04; 0.79] | | Mortalité totale 1.71 [0.51; 5.75] IDM fatal 0.98 [0.14; 6.87] Mortalité vasculaire 1.22 [0.33; 4.48] AVC fatal 1.96 [0.18; 21.39] AVC non fatal 0.33 [0.07; 1.59] IDM non fatal 0.00 [0.00; NaN] | PHS (diabetics sub group), 1989 | aspirin vs placebo | CHD events (fatal and non fatal) 0.40 [0.20; 0.79] | | | PPP (diabetics sub group), 2003 | aspirin vs no treatment | | | All cause mortality 1.23 [0.69; 2.19] CHD events (fatal and non fatal) 0.49 [0.17; 1.43] CV death 1.23 [0.49; 3.10] revascularization procedure 0.79 [0.31; 1.98] stroke (fatal and non fatal) 0.89 [0.36; 2.17] all MI 0.49 [0.17; 1.43] CV events (fatal and non fatal) 0.90 [0.50; 1.62] peripheral artery disease 0.83 [0.38; 1.85] stable angina 0.80 [0.39; 1.65] | WHS (diabetics sub group), 2005 | aspirin vs placebo | stroke (fatal and non fatal) 0.48 [0.26; 0.88] | | CHD events (fatal and non fatal) 1.50 [0.91; 2.47] all MI 1.50 [0.91; 2.47] CV events (fatal and non fatal) 0.93 [0.67; 1.31] |
Trial | Treatments | Patients | Method |
---|
CDPA, 1976 | Aspirin (324 mg) 3x/d (n=758) vs. Placebo (n=771) | MI survivors | Double blind Parallel groups Sample size: 758/771 Primary endpoint: No primary outcome clearly defined FU duration: 1.83 y | Cardiff I, 1974 | Aspirin (300 mg) 1x/d (n=615) vs. Placebo (n=624) | MI survivors | Double blind Parallel groups Sample size: 615/624 Primary endpoint: Total mortality FU duration: 2 years | Cardiff II, 1979 | Aspirin (300 mg) 3x/d for one year (n=832) vs. Placebo (n=850) | patients with myocardial infarction | Double blind Parallel groups Sample size: 832/850 Primary endpoint: Total mortality FU duration: 1 y | Vogel, 1979 | Aspirin (1.5 g daily) on an average period of 22 months
(n=672) vs. Placebo
(n=668) | | Double blind Parallel groups Sample size: 672/668 Primary endpoint: Death or reinfraction FU duration: 1.75 y (mean) | AMIS, 1980 | Aspirin (500 mg) 2x/d for at least 3 years (n=2267) vs. Placebo (n=2257) | men and women who had had a documented myocardial infarction | Double blind Parallel groups Sample size: 2267/2257 Primary endpoint: Total mortality FU duration: > 3 y | GAMIS, 1980 | Aspirin (500 mg) 3x/d for 2 years (n=317) vs. Placebo (n=309) | patients who had survived a myocardial infarction for 30-42 days | Double blind Parallel groups Sample size: 317/309 Primary endpoint: No primary outcome clearly defined FU duration: 2 y part of a 3-group trial | PARIS, 1980 | Aspirin (324 mg) 3x/d (n=810) vs. Placebo (n=406) | patients who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/406 Primary endpoint: No primary outcome clearly defined FU duration: 41 mo part of 3-group trial | JAMIS, 1999 | Aspirin (81 mg) 1x/d (n=250) vs. No antiplatelets (n=230) | patients with AMI within 1 month from the onset of symptoms | Open Parallel groups Sample size: 250/230 Primary endpoint: No primary outcome clearly defined FU duration: 1.3 y (mean) part of a 3-group trial | Schoop, 1983 | groupe 1 : Aspirine 990 mg / j
(pour mémoire : groupe 2 : Aspirine 990 mg / j + dipyridamole 225 mg/j) (n=100) vs. Placebo (n=100) Données isuues de la méta-analyse ATC | AOMI stade non précisé | double blind Parallel groups Sample size: 100/100 Primary endpoint: Progression de l’athérosclérose FU duration: <5 y | Hess, 1985 | groupe 1 : Aspirine 330 mg / j
(pour mémoire : groupe 2 : Aspirine 330 mg / j + dipyridamole 75 mg / j) (n=80) vs. Placebo (n=80) | AOMI stade non précisé | single blind Parallel groups Sample size: 80/80 Primary endpoint: Score de progression de l’athérosclérose FU duration: | Munich A, 1975 | Aspirine: 1500 mg / jour (n=92) vs. Placebo (n=84) | Données non disponibles | double blind Parallel groups Sample size: 92/84 Primary endpoint: FU duration: | Munich B, 1975 | Aspirine 1500 mg / jour pendant 24 mois (n=42) vs. Placebo (n=40) | NA | double blind Parallel groups Sample size: 42/40 Primary endpoint: FU duration: | SAPAT, 1992 | aspirin 75 mg daily (n=1009) vs. placebo (n=1026) | patients with stable chronic angina pectoris | double blind Parallel groups Sample size: 1009/1026 Primary endpoint: myocardial infarction and sudden death FU duration: 50 months | POPADAD aspirin, 2008 | aspirin 100mg daily (n=638) vs. placebo (n=638) factoral design with antioxidant capsule | patients with diabetes mellitus and asymptomatic peripheral arterial disease | double blind Factorial plan Sample size: 638/638 Primary endpoint: Cv events; CHD death+stroke FU duration: nov 1997 - jul 2001 | JPAD, 2008 | low-dose aspirin (81 or 100 mg per day) (n=1262) vs. no aspirin (n=1277) | patients with type 2 diabetes without a history of atherosclerotic disease | open Parallel groups Sample size: 1262/1277 Primary endpoint: atherosclerotic events FU duration: 4.37 y median | DAMAD, 1989 | aspirin alone (330 mg 3 times daily) or in combination with dipyridamole (75 mg 3 times daily) (n=318) vs. placebo (n=157) | patients with early diabetic retinopathy | double blind Parallel groups Sample size: 318/157 Primary endpoint: number of microaneurysms FU duration: 3 y | ETDRS, 1992 | aspirin 650mg once daily (n=1856) vs. placebo (n=1855) | patients with diabetes mellitus (Type I or II) | double blind Parallel groups Sample size: 1856/1855 Primary endpoint: Mortality from all causes FU duration: 60 months | CLIPS, 2007 | oral aspirin 100 mg daily (n=185) vs. placebo (n=181) factorial design with 2nd factor antioxidant vitamins (600mg vit E, 250mg vit C and 20mg beta-caroteen daily) vs placebo | outpatients with stage I-II PAD documented by angiography or ultrasound, with ankle/brachial index <0.85 or toe index <0.6 | double blind Factorial plan Sample size: 185/181 Primary endpoint: cardiovascular death, myocardial infarction, stroke, critical leg ischaemia FU duration: 20.7 months mean | PHS (diabetics sub group), 1989 | aspirin 325 mg every other day (n=275) vs. placebo (n=258) | healthy men (diabetic sub group of patients enrolled if PHS) | double blind Factorial plan Sample size: 275/258 Primary endpoint: cardiovascular mortality FU duration: 5 y | PPP (diabetics sub group), 2003 | aspirin 100mg daily (n=519) vs. control (n=512) factorial design evaluating aspirin and vitamin E | men and women with diabetes and without a previous cardiovascular event aged >50 with >=1 risk factors for cardiovascular disease - sub group of diabetic patients Initialy, PPP enrolled 4784 patients of whom 1031 had diabetes | open Factorial plan Sample size: 519/512 Primary endpoint: CV events FU duration: 3.6 y sub group study | WHS (diabetics sub group), 2005 | aspirin 100mg on alternate days (n=514) vs. placebo (n=513) factorial design of aspirin and vitamin E | healthy women 45 years of age or older - diabetics sub groups trial enrolled 39876 patients of whom 1027 had diabetes (2.6%) | double blind Parallel groups Sample size: 514/513 Primary endpoint: cardiovascular event FU duration: 10.1 y sub group |
|
cardiovascular prevention | aspirin | primary prevention | versus placebo or control No demonstrated result for efficacy aspirin inferior to placebo in terms of Major gastrointestinal bleeding in Physicians Health Study, 1989 (primary prevention patients) aspirin inferior to placebo in terms of Major extracranial bleed in HOT, 1998 (primary prevention patients) aspirin inferior to placebo in terms of Gastrointestinal Bleeding in HOT, 1998 (primary prevention patients) aspirin inferior to placebo in terms of Major gastrointestinal bleeding in HOT, 1998 (primary prevention patients) aspirin inferior to no treatment in terms of Gastrointestinal Bleeding in Primary Prevention Project, 2001 (primary prevention patients) aspirin inferior to placebo in terms of Gastrointestinal Bleeding in Women’s Health Study, 2005 (primary prevention patients) aspirin inferior to placebo in terms of Peptic ulcer in Women’s Health Study, 2005 (primary prevention patients) aspirin inferior to placebo in terms of Hematuria in Women’s Health Study, 2005 (primary prevention patients) aspirin inferior to placebo in terms of Major gastrointestinal bleeding in Women’s Health Study, 2005 (primary prevention patients) | 6 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
British Doctor’s Trial, 1988 | aspirin vs no treatment | | | all-cause mortality 0.89 [0.74; 1.08] coronary heart disease mortality 0.94 [0.67; 1.34] total coronary heart disease events 0.96 [0.75; 1.23] Cv death 0.93 [0.72; 1.22] Hemorrhagic Stroke and Intracranial Hemorrhage 1.08 [0.41; 2.84] non fatal stroke 1.13 [0.72; 1.77] non fatal MI 0.97 [0.67; 1.41] Ischemic Stroke 1.50 [0.64; 3.51] fatal and nonfatal stroke 1.16 [0.80; 1.69] CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.98 [0.81; 1.19] Major gastrointestinal bleeding 1.00 [0.47; 2.13] | Physicians Health Study, 1989 | aspirin vs placebo | coronary heart disease mortality 0.64 [0.42; 0.99] total coronary heart disease events 0.61 [0.51; 0.74] non fatal MI 0.61 [0.49; 0.75] CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.83 [0.71; 0.96] | Major gastrointestinal bleeding 1.60 [1.01; 2.52] | all-cause mortality 0.96 [0.79; 1.15] Cv death 0.98 [0.72; 1.32] Hemorrhagic Stroke and Intracranial Hemorrhage 1.92 [0.95; 3.85] non fatal stroke 1.20 [0.91; 1.57] Ischemic Stroke 1.11 [0.82; 1.49] fatal and nonfatal stroke 1.21 [0.93; 1.58] | Thrombosis Prevention Trial, 1998 | aspirin vs placebo | non fatal MI 0.68 [0.53; 0.89] | | Major extracranial bleed 1.54 [0.77; 3.08] all-cause mortality 1.03 [0.79; 1.33] coronary heart disease mortality 1.06 [0.66; 1.68] total coronary heart disease events 0.77 [0.58; 1.03] Cv death 1.24 [0.93; 1.66] Hemorrhagic Stroke and Intracranial Hemorrhage 2.00 [0.75; 5.31] non fatal stroke 0.78 [0.50; 1.23] Ischemic Stroke 0.64 [0.37; 1.09] fatal and nonfatal stroke 0.69 [0.38; 1.26] CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.88 [0.74; 1.04] Major gastrointestinal bleeding 1.54 [0.77; 3.08] | HOT, 1998 | aspirin vs placebo | total coronary heart disease events 0.65 [0.49; 0.85] non fatal MI 0.60 [0.44; 0.80] myocardial infarction (fatal and non fatal) 0.65 [0.49; 0.85] CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.86 [0.74; 0.99] | Major extracranial bleed 1.93 [1.43; 2.62] Gastrointestinal Bleeding 1.94 [1.41; 2.69] Major gastrointestinal bleeding 2.08 [1.41; 3.07] | all-cause mortality 0.93 [0.79; 1.09] coronary heart disease mortality 1.00 [0.48; 2.09] Cv death 0.95 [0.75; 1.20] Hemorrhagic Stroke and Intracranial Hemorrhage 0.93 [0.45; 1.93] fatal bleeding 0.87 [0.32; 2.41] fatal and nonfatal stroke 0.99 [0.79; 1.24] | Primary Prevention Project, 2001 | aspirin vs no treatment | | Gastrointestinal Bleeding 3.47 [1.28; 9.38] | all-cause mortality 0.81 [0.58; 1.13] coronary heart disease mortality 0.86 [0.39; 1.92] total coronary heart disease events 0.76 [0.46; 1.25] Hemorrhagic Stroke and Intracranial Hemorrhage 0.68 [0.11; 4.06] non fatal MI 0.73 [0.38; 1.41] Ischemic Stroke 0.95 [0.46; 1.97] fatal and nonfatal stroke 0.68 [0.36; 1.28] myocardial infarction (fatal and non fatal) 0.69 [0.39; 1.23] CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.72 [0.49; 1.04] Major gastrointestinal bleeding 2.04 [0.51; 8.14] | Women’s Health Study, 2005 | aspirin vs placebo | Ischemic Stroke 0.77 [0.63; 0.94] fatal and nonfatal stroke 0.83 [0.70; 0.99] | Gastrointestinal Bleeding 1.21 [1.10; 1.33] Peptic ulcer 1.31 [1.16; 1.49] Hematuria 1.06 [1.01; 1.11] Major gastrointestinal bleeding 1.40 [1.07; 1.83] | all-cause mortality 0.95 [0.85; 1.06] coronary heart disease mortality 1.17 [0.54; 2.52] total coronary heart disease events 0.97 [0.82; 1.16] Hemorrhagic Stroke and Intracranial Hemorrhage 1.24 [0.83; 1.88] non fatal MI 1.02 [0.83; 1.25] myocardial infarction (fatal and non fatal) 1.03 [0.84; 1.25] CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.91 [0.81; 1.03] |
Trial | Treatments | Patients | Method |
---|
British Doctor’s Trial, 1988 | aspirin 500 mg/d (n=3429) vs. no aspirin (n=1710) | apparently healthy male doctors | open Parallel groups Sample size: 3429/1710 Primary endpoint: not defined FU duration: 5.5 years | Physicians Health Study, 1989 | aspirin 325 mg every other day (n=11037) vs. placebo (n=11034) factorial design with beta caroten vs placebo | Healthy men | double blind Parallel groups Sample size: 11037/11034 Primary endpoint: cardiovascular mortality ? FU duration: 60.2 months | Thrombosis Prevention Trial, 1998 | aspirin 75 mg/d (controlled release) (n=2545) vs. placebo (n=2540) factorial design of aspirin and warfarin (all two vs placebo) | Men at high risk of CHD | double blind Factorial plan Sample size: 2545/2540 Primary endpoint: ischemic heart diseases FU duration: median 6.8y | HOT, 1998 | aspirin 75 mg daily (n=9399) vs. placebo (n=9391) factorial design with as 2nd factor the comparison of 3 BP targets | patients aged 50-80 with hypertension and diastolic blood pressure between 100 mmHG and 115 mmHG | Double blind Factorial plan Sample size: 9399/9391 Primary endpoint: non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death FU duration: mean 3.8 y (range 3.3-4.9y) | Primary Prevention Project, 2001 | aspirin 100 mg/d (n=2226) vs. no aspirin (open control) (n=2269) factorial design with other comaprison: vitamin E vs control | men and women aged 50 years or greater, with at least one of the major recognised cardiovascular risk factors. | Open Factorial plan Sample size: 2226/2269 Primary endpoint: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke FU duration: 3.6 y | Women’s Health Study, 2005 | aspirin 100mg daily (n=19934) vs. placebo (n=19942) factorial design: vitamin E vs placebo | initially healthy women 45 years of age or older | Double blind Factorial plan Sample size: 19934/19942 Primary endpoint: nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular causes FU duration: 10.1 y mean (range 8.2 to 10.9 |
|
cardiovascular prevention | aspirin | secondary prevention | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
AAA, 2009 | aspirin vs placebo | | | fatal or nonfatal coronary event or stroke or revascularisation 1.03 [0.84; 1.27] major haemorrhage requiring admission to hospital 1.71 [0.99; 2.96] All cause mortality 0.95 [0.77; 1.17] Major hemorrhage 1.70 [0.98; 2.94] all vascular event 1.00 [0.85; 1.17] gastrointestinal ulcer 1.75 [0.74; 4.16] fatal hemorrhagic stroke 1.00 [0.20; 4.95] non fatal hemorrhagic stroke 2.00 [0.18; 22.04] |
Trial | Treatments | Patients | Method |
---|
AAA, 2009 | aspirin 100mg daily (n=1675) vs. placebo (n=1675) | men and women aged 50 to 80 years with asymptomatic atherosclerosis detected by low ankle brachial index (<=0.95) | double blind Parallel groups Sample size: 1675/1675 Primary endpoint: fatal or nonfatal coronary event or stroke or revascularisation FU duration: 8.2 y (mean) |
|
cardiovascular prevention | clopidogrel | not classified | versus aspirin No demonstrated result for efficacy | 2 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
CAPRIE (PAD subgroup), 1996 | clopidogrel vs aspirin | IDM fatal 0.62 [0.44; 0.88] IDM totaux 0.63 [0.47; 0.85] | | Mortalité totale 0.81 [0.63; 1.06] AVC fatal 0.95 [0.69; 1.31] AVC non fatal 1.38 [0.55; 3.42] IDM non fatal 0.67 [0.37; 1.21] | ASCET | clopidogrel vs aspirin | | | vascular event 0.90 [0.63; 1.29] |
Trial | Treatments | Patients | Method |
---|
CAPRIE (PAD subgroup), 1996 | Clopidogrel 75 mg (n=3223) vs. Aspirine 325 mg (n=3229) | patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease Effectifs correspondant à la strate AOMI | double blind Parallel groups Sample size: 3223/3229 Primary endpoint: Critère composite FU duration: 1.91 y | ASCET | clopidogrel 75 mg once daily for two years (n=498) vs. Aspirin 160 mg once daily for two years (n=503) | patients with documented coronary heart disease and treated with aspirin platelet function was also assessed at randomization with the PFA100 method and platelet aggregometry | open Parallel groups Sample size: 498/503 Primary endpoint: all-cause death, nonfatal MI, ischemic stroke, and unstable angina FU duration: |
|
cardiovascular prevention | clopidogrel | secondary prevention | versus aspirin No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
CAPRIE, 1996 | clopidogrel vs aspirin | Non fatal MI 0.84 [0.70; 1.00] MI,stroke or CVdeath 0.92 [0.84; 1.00] | | Death from any cause 0.98 [0.87; 1.10] Death from cardiovascular causes 0.92 [0.80; 1.07] severe bleeding 0.88 [0.70; 1.12] non fatal stroke 0.94 [0.82; 1.07] |
Trial | Treatments | Patients | Method |
---|
CAPRIE, 1996 | clopidogrel 75 mg once daily (n=9599) vs. aspirin 325 mg once daily (n=9586) | patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease | Double blind Parallel groups Sample size: 9599/9586 Primary endpoint: ischaemic stroke, myocardial infarction, or vascular death FU duration: mean 1.91 years |
|
cardiovascular prevention | clopidogrel | secondary prevention | versus placebo or control No demonstrated result for efficacy clopidogrel inferior to placebo (on top aspirin) in terms of moderate bleeding in CHARISMA, 2006 (secondary prevention patients) | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
CHARISMA, 2006 | clopidogrel vs placebo (on top aspirin) | non fatal stroke 0.81 [0.65; 1.00] | moderate bleeding 1.62 [1.27; 2.08] | nonfatal Ischemic stroke 0.82 [0.66; 1.04] Death from any cause 0.99 [0.86; 1.14] Death from cardiovascular causes 1.04 [0.87; 1.24] severe bleeding 1.25 [0.97; 1.61] Non fatal MI 0.92 [0.74; 1.15] fatal bleeding 1.53 [0.83; 2.82] MI,stroke or CVdeath 0.93 [0.83; 1.04] |
Trial | Treatments | Patients | Method |
---|
CHARISMA, 2006 | clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) (n=7802) vs. placebo plus low-dose aspirin (n=7801) | patients with either clinically evident cardiovascular disease or multiple risk factors | Double blind Parallel groups Sample size: 7802/7801 Primary endpoint: myocardial infarction, stroke or death from cardiovasculare causes FU duration: median 28 months |
|
cardiovascular prevention | dipyridamol | not classified | versus placebo or control No demonstrated result for efficacy | 15 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
PARIS, 1980 | dipyridamol + aspirin vs placebo | | | Stroke 0.63 [0.25; 1.58] | PARIS-II, 1986 | dipyridamol + aspirin vs placebo | | | Stroke 0.61 [0.35; 1.05] | | aspirin + dipyridamol vs placebo | | | | | aspirin + dipyridamol vs placebo | | | | | aspirin + dipyridamol vs placebo | | | | Atlanta (Sbar), 1967 | dipyridamol vs control | | | vascular death ∞ [NaN; ∞] Non fatal stroke ∞ [NaN; ∞] Non fatal MI 0.75 [0.18; 3.07] non vascular death NaN [NaN; NaN] vascular event 1.25 [0.37; 4.21] | Becker, 1967 | dipyridamol vs control | | | vascular death ∞ [NaN; ∞] Non fatal stroke NaN [NaN; NaN] Non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event ∞ [NaN; ∞] | Wirecki, 1967 | dipyridamol vs control | | | vascular death NaN [NaN; NaN] Non fatal stroke NaN [NaN; NaN] Non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event NaN [NaN; NaN] | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | | | dipyridamol vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810) vs. Placebo (n=406) | patients who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/406 Primary endpoint: No primary outcome clearly defined FU duration: 41 months (mean) part of 3-group trial | PARIS-II, 1986 | Aspirin (330 mg) + dipyridamole (75 mg) 3x/d (n=1563) vs. Placebo (n=1565) | patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously | Double blind Parallel groups Sample size: 1563/1565 Primary endpoint: No primary outcome clearly defined FU duration: 23.4 months | Hess (2), 1985 | Aspirine Dipyridamole 330 mg / j 225 mg / j (n=80) vs. Placebo (n=80) | patients with occlusive arterial disease in the lower extremities | double blind Parallel groups Sample size: 80/80 Primary endpoint: Score de progression de l’athérosclérose FU duration: | Schoop (2), 1983 | Aspirine Dipyridamole 990 mg / j 225 mg /j (n=100) vs. Placebo (n=100) | AOMI stade non précisé | double blind Parallel groups Sample size: 100/100 Primary endpoint: Progression de l’athérosclérose FU duration: | VA study, 1986 | Aspirine + Dipyridamole 975 mg / j 225 mg /j (n=110) vs. Placebo (n=121) | non-insulin-dependent diabetic men with either a recent amputation for gangrene or active gangrene | double blind Parallel groups Sample size: 110/121 Primary endpoint: Mortalité due à une pathologie vasculaire athérosclérotique ou amputation pour gangrène au membre op FU duration: 46 months | Atlanta (Sbar), 1967 | dipyridamole 150mg daily (n=30) vs. placebo (n=30) | patients with angina pectoris | double-blind parallel groups Sample size: 30/30 Primary endpoint: not defined FU duration: 6 months | Becker, 1967 | dipyridamole 225mg daily (n=14) vs. placebo (n=13) | | double-blind parallel groups Sample size: 14/13 Primary endpoint: not defined FU duration: 5 months | Wirecki, 1967 | dipyridamole 150mg daily (n=28) vs. placebo (n=28) | patients with angina pectoris | double blind parallel groups Sample size: 28/28 Primary endpoint: not defined FU duration: 7 months | Igloe, 1970 | Dipyridamole 200mg daily (n=26) vs. placebo (n=22) | patients with angina pectoris | double blind parallel groups Sample size: 26/22 Primary endpoint: not defined FU duration: 2-7 months | Zion, 1961 | Dipyridamole 37.5mg (n=14) vs. placebo (n=14) | patients with angina pectoris | double-blind cross-over Sample size: 14/14 Primary endpoint: not defined FU duration: 0.5 months | Kinsella, 1962 | dipyridamole 37.5 mg and 100mg daily (n=13) vs. placebo (n=13) | | double-blind parallel groups Sample size: 13/13 Primary endpoint: not defined FU duration: 0.5 months | Leiberman, 1964 | dipyridamole 100mg daily (n=19) vs. placebo (n=19) | | double blind parallel groups Sample size: 19/19 Primary endpoint: not defined FU duration: >3 months | Dewar, 1961 | Dipyridamole 100mg daily (n=17) vs. placebo (n=17) | patients with angina pectoris | double-blind parallel groups Sample size: 17/17 Primary endpoint: not defined FU duration: 0.5 months | Neumann, 1964 | dipyridamole 150mg daily (n=20) vs. placebo (n=16) | elderly with precordial pain | double-blind parallel groups Sample size: 20/16 Primary endpoint: not defined FU duration: 1.5 months | Foulds, 1960 | Dipyridamole 200mg daily (n=24) vs. placebo (n=24) | patients with angina pectoris | double-blind parallel groups Sample size: 24/24 Primary endpoint: not defined FU duration: 1 months |
|
cardiovascular prevention | dipyridamol | not classified | versus aspirin No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
PARIS, 1980 | dipyridamol + aspirin vs aspirin | | | Death or nonfatal MI 1.05 [0.84; 1.30] |
Trial | Treatments | Patients | Method |
---|
PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810) vs. Aspirin (324 mg) 3x/d (n=810) | patuents who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/810 Primary endpoint: No primary outcome clearly defined FU duration: 41 months part of 3-group trial |
|
cardiovascular prevention | ketanserine | not classified | versus placebo or control No demonstrated result for efficacy | 3 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| ketanserine vs placebo | | | | | ketanserine vs placebo | | | | | ketanserine vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
PACK, 1996 | Ketanserin 40 mg / j pdt 1 mois 80 mg / j ensuite (n=1930) vs. Placebo (n=1969) | patients over 40 years old who had had documented intermittent claudication for at least two months and in whom the ratio of systolic blood pressure in the ankle to that in the arm was less than or equal to 0.85 in both arteries of at least one foot | double blind Parallel groups Sample size: 1930/1969 Primary endpoint: IDM, AVC majeur, amputation au dessus de la cheville pour des raisons autres que tumorales ou trauma FU duration: 1 y | Walden, 1991 | Ketanserin 60 mg / j pdt 1 mois 120 mg / j ensuite (n=17) vs. Placebo (n=18) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: 17/18 Primary endpoint: Périmètre de marche FU duration: 15 months | Thulesius, 1987 | Ketanserin 60 mg / j pdt 2 semaines 120 mg / j ensuite (n=79) vs. Placebo (n=86) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: 79/86 Primary endpoint: Périmètre de marche FU duration: 6 months |
|
cardiovascular prevention | picotamide | not classified | versus placebo or control No demonstrated result for efficacy | 4 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| picotamide vs placebo | | | | | picotamide vs placebo | | | | | picotamide vs placebo | | | | Cocozza, 1995 | picotamide vs placebo | | | CV death 0.00 [0.00; NaN] non fatal MI 0.00 [0.00; NaN] CV events (fatal and non fatal) 0.00 [0.00; NaN] |
Trial | Treatments | Patients | Method |
---|
ADEP, 1993 | Picotamide 600 mg / j (n=1150) vs. Placebo (n=1154) | patients with peripheral obstructive arterial disease (stade II+) | double blind Parallel groups Sample size: 1150/1154 Primary endpoint: Mortalité vasculaire et non vasculaire, IDM fatal ou non, AVC fatal ou non, amputation au dessus de FU duration: 18 months | Neirotti, 1994 | Picotamide 900 mg / j (n=10) vs. Placebo (n=10) | patients with peripheral arterial disease (PAD) at functional stage 2 of the Fontaine classification and with intermittent claudication for at least six months | double blind Parallel groups Sample size: 10/10 Primary endpoint: Paramètres hémodynamiques, de coagulation, d’activité plaquettaire FU duration: 18 months | Coto, 1989 | Picotamide 900 mg / j (n=20) vs. Placebo (n=20) | patients with peripheral occlusive arterial disease of the lower limbs at functional stage II of the Fontaine classification | double blind Parallel groups Sample size: 20/20 Primary endpoint: Périmètres de marche, paramètres sanguins FU duration: 6 months | Cocozza, 1995 | picotamide 300 mg TID (n=25) vs. placebo (n=25) | normotensive diabetic patients with asymptomatic mild or moderate nonstenotic (< 50%) carotid atherosclerotic lesions and negative history of cerebrovascular ischemic events | double blind Parallel groups Sample size: 25/25 Primary endpoint: not unique (carotid atherosclerotic lesions) FU duration: 24 months |
|
cardiovascular prevention | sulfinpyrazone | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Dutch, 1980 | sulfinyrazone vs placebo | | | All cause mortality ∞ [NaN; ∞] CV death ∞ [NaN; ∞] non fatal MI 1.00 [0.05; 18.57] CV events (fatal and non fatal) 2.07 [0.41; 10.46] |
Trial | Treatments | Patients | Method |
---|
Dutch, 1980 | sulfinyrazone (n=30) vs. (n=31) | | Parallel groups Sample size: 30/31 Primary endpoint: FU duration: 32 months |
|
cardiovascular prevention | suloctidil | not classified | versus placebo or control No demonstrated result for efficacy | 4 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| suloctidil vs placebo | | | | | suloctidil vs placebo | | | | | suloctidil vs placebo | | | | | suloctidil vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
Adriaensen, 1976 | Suloctidil 200 mg / j (n=15) vs. Placebo (n=15) | patients suffering from intermittent claudication ( stade II) | double blind Parallel groups Sample size: 15/15 Primary endpoint: Périmètre de marche FU duration: 2 months | Verhaeghe, 1981 | Suloctidil 200 mg / j (n=-9) vs. Placebo (n=-9) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: -9/-9 Primary endpoint: Périmètre de marche FU duration: 6 months | Jones, 1982 | Suloctidil 300 mg / j (n=18) vs. Placebo (n=22) | patients suffering from intermittent claudication (stade II) | double blind Parallel groups Sample size: 18/22 Primary endpoint: Périmètre de marche, pression à la cheville, flux sanguin musculaire FU duration: 6 months | Holm, 1984 | Suloctidil 300 mg / j (n=20) vs. Placebo (n=20) | AOMI stade II | double blind Parallel groups Sample size: 20/20 Primary endpoint: Périmètre de marche, pression à la cheville, flux sanguin musculaire FU duration: 2.75 y |
|
cardiovascular prevention | ticagrelor | not classified | versus No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
EUCLID, 2016 | ticagrelor vs clopidogrel | | | |
Trial | Treatments | Patients | Method |
---|
EUCLID, 2016 | ticagrelor (90 mg twice daily) (n=-9) vs. clopidogrel (75 mg once daily) (n=-9) | patients with symptomatic peripheral artery disease | Sample size: -9/-9 Primary endpoint: FU duration: 30 months (median) |
|
cardiovascular prevention | ticagrelor | secondary prevention | versus placebo or control No demonstrated result for efficacy ticagrelor inferior to placebo (on top aspirin) in terms of Major hemorrhage in PEGASUS 60mg, 2015 (secondary prevention patients) ticagrelor inferior to placebo (on top aspirin) in terms of Major hemorrhage in PEGASUS 90mg, 2015 (secondary prevention patients) | 2 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
PEGASUS 60mg, 2015 | ticagrelor vs placebo (on top aspirin) | Stroke (any) 0.75 [0.57; 0.98] myocardial infarction 0.85 [0.73; 0.99] all vascular event 0.85 [0.75; 0.95] CV death, MI, stroke 0.85 [0.75; 0.95] | Major hemorrhage 2.16 [1.56; 2.99] | All cause mortality 0.89 [0.76; 1.04] death from CHD 0.81 [0.63; 1.04] cardiovascular death 0.83 [0.68; 1.01] fatal bleeding 0.92 [0.41; 2.08] Intracranial haemorrhage 1.10 [0.67; 1.81] | PEGASUS 90mg, 2015 | ticagrelor vs placebo (on top aspirin) | death from CHD 0.74 [0.57; 0.96] myocardial infarction 0.82 [0.70; 0.95] all vascular event 0.85 [0.76; 0.96] CV death, MI, stroke 0.85 [0.76; 0.96] | Major hemorrhage 2.36 [1.72; 3.24] | All cause mortality 1.00 [0.86; 1.16] cardiovascular death 0.87 [0.71; 1.06] fatal bleeding 0.50 [0.19; 1.33] Intracranial haemorrhage 1.26 [0.73; 2.18] Stroke (any) 0.82 [0.63; 1.07] |
Trial | Treatments | Patients | Method |
---|
PEGASUS 60mg, 2015 | ticagrelor at a dose of 60 mg twice daily (n=7045) vs. placebo (n=7067) | patients who had
had a myocardial infarction 1 to 3 years earlier | double-blind Parallel groups Sample size: 7045/7067 Primary endpoint: cardiovascular death, myocardial FU duration: 2.75 y (median) | PEGASUS 90mg, 2015 | ticagrelor at a dose of 90 mg twice daily
(n=7050) vs. (n=7067)
| patients who had
had a myocardial infarction 1 to 3 years earlier
| double-blind Sample size: 7050/7067 Primary endpoint: cardiovascular death, myocardial FU duration: 2.75 y (median)
|
|
cardiovascular prevention | ticlopidine | not classified | versus placebo or control No demonstrated result for efficacy | 17 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | Berglund, 1985 | ticlopidine vs placebo | | | vascular death NaN [NaN; NaN] Non fatal stroke NaN [NaN; NaN] Non fatal MI NaN [NaN; NaN] non vascular death NaN [NaN; NaN] vascular event NaN [NaN; NaN] | Birmingham-A, 1979 | ticlopidine vs placebo | | | All cause mortality NaN [NaN; NaN] CV death NaN [NaN; NaN] non fatal MI 0.00 [0.00; NaN] CV events (fatal and non fatal) 0.00 [0.00; NaN] | London diabetes, 1983 | ticlopidine vs placebo | | | All cause mortality 1.05 [0.07; 16.24] CV death 1.05 [0.07; 16.24] non fatal MI NaN [NaN; NaN] CV events (fatal and non fatal) 0.53 [0.05; 5.57] | TIMAD, 1984 | ticlopidine vs placebo | | | All cause mortality 0.73 [0.17; 3.24] CV death 0.49 [0.04; 5.35] non fatal MI 0.33 [0.03; 3.84] CV events (fatal and non fatal) 0.56 [0.17; 1.88] | BTRS, 1992 | ticlopidine vs placebo | | | All cause mortality NaN [NaN; NaN] CV death NaN [NaN; NaN] non fatal MI 0.00 [0.00; NaN] CV events (fatal and non fatal) 0.00 [0.00; NaN] | Nyberg, 1984 | ticlopidine vs placebo | | | All cause mortality ∞ [NaN; ∞] CV death ∞ [NaN; ∞] non fatal MI NaN [NaN; NaN] CV events (fatal and non fatal) ∞ [NaN; ∞] |
Trial | Treatments | Patients | Method |
---|
EMATAP, 1993 | Ticlopidine 500 mg/j (n=304) vs. Placebo (n=311) | AOMI stade non précisé | double blind Parallel groups Sample size: 304/311 Primary endpoint: Mortalité subite, IDM, AVC, intervention chirurgicale liée à une aggravation clinique FU duration: | Katsumara, 1982 | Ticlopidine 500 mg/j (n=93) vs. Placebo (n=100) | patients with ischemic ulcers due to chronic arterial occlusion | double blind Parallel groups Sample size: 93/100 Primary endpoint: Taille / cicatrisation des ulcères FU duration: 6 semaines | Aukland, 1982 | Ticlopidine 500 mg/j (n=33) vs. Placebo (n=32) | men with atherosclerotic intermittent claudication and haemorheological abnormalities | double blind Parallel groups Sample size: 33/32 Primary endpoint: Périmètre de marche, pressionsystolique à la cheville FU duration: 1 y | Stiegler, 1984 | Ticlopidine 500 mg/j (n=57) vs. Placebo (n=57) | AOMI stade II | double blind Parallel groups Sample size: 57/57 Primary endpoint: Score de progression de l’athérosclérose FU duration: | Ellis, 1986 | Ticlopidine 500 mg/j (n=100) vs. Placebo (n=103) | AOMI stade II | double blind Parallel groups Sample size: 100/103 Primary endpoint: Périmètre de marche FU duration: 6 months | Cloarec, 1986 | Ticlopidine 500 mg/j (n=66) vs. Placebo (n=66) | AOMI stade non précisé | double blind Parallel groups Sample size: 66/66 Primary endpoint: Périmètre de marche FU duration: 1 y | Arcan, 1988 | Ticlopidine 500 mg/j (n=83) vs. Placebo (n=86) | patients with chronic intermittent claudication due to obstructive peripheral vascular disease (stade II) | double blind Parallel groups Sample size: 83/86 Primary endpoint: Périmètre de marche FU duration: 6 months randomisation centralisée | Balsano, 1989 | Ticlopidine 500 mg/j (n=76) vs. Placebo (n=75) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: 76/75 Primary endpoint: Périmètre de marche FU duration: 21 months | STIMS, 1990 | Ticlopidine 500 mg/j (n=346) vs. Placebo (n=341) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: 346/341 Primary endpoint: IDM, AVC, AIT FU duration: 5.6 y | Hurlow, 1980 | Ticlopidine : 100 -500 mg / jour pendant 2 mois. (n=30) vs. Placebo (n=30) | Données non disponibles | double blind Parallel groups Sample size: 30/30 Primary endpoint: FU duration: | Krause, 1980 | Ticlopidine : 500 mg pendant 4 mois (n=19) vs. Placebo (n=19) | Données non disponibles | double blind Parallel groups Sample size: 19/19 Primary endpoint: FU duration: | Berglund, 1985 | ticlopidine 500 mg daily (n=21) vs. placebo (n=17) | middle-aged men with stable incapacitating angina pectoris | double blind parallel groups Sample size: 21/17 Primary endpoint: not defined FU duration: 2m | Birmingham-A, 1979 | ticlopidine 100, 250, 500 mg (n=20) vs. (n=8) | | Parallel groups Sample size: 20/8 Primary endpoint: FU duration: 2 months | London diabetes, 1983 | ticlopidine 500mg (n=38) vs. (n=40) | | Parallel groups Sample size: 38/40 Primary endpoint: FU duration: 12 months | TIMAD, 1984 | ticlopidine 500mg (n=220) vs. (n=215) | | Parallel groups Sample size: 220/215 Primary endpoint: FU duration: 32m | BTRS, 1992 | ticlopidine 500mg/d (n=49) vs. placebo (n=51) | insulin-treated diabetics with background retinopathy | double blind Parallel groups Sample size: 49/51 Primary endpoint: evolution of retinopathy FU duration: 48 months | Nyberg, 1984 | ticlopidine 500mg daily (n=12) vs. placebo (n=11) | insulin dependent diabetes complicated by nephropathy | double blind Parallel groups Sample size: 12/11 Primary endpoint: FU duration: 12 months |
|
cardiovascular prevention | various | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| cloricromene vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
CRAMPS, 2000 | Cloricromène : 100 mg, 2 fois / jour / voie orale + aspirine : 160 mg / jour pendant 6 mois . (n=81) vs. placebo + aspirine: 160 mg/ jour pendant 6 mois. (n=78) | Stade de la maladie : II, pendant 3.1 années d'ancienneté en moyenne dans les 2 groupes
| double blind Parallel groups Sample size: 81/78 Primary endpoint: périmètre de marche ( maximal, sans douleur) FU duration: 6 months Tous les pts ont été admis dans une période de run-in de 3 semaines en simple aveugle : avec prise d'1 cp de placebo, 2 fois / jour, afin d'évaluer leur éligiblité dans la période en double aveugle de l'essai.
Randomisation centralisée |
|
cardiovascular prevention | vorapaxar | secondary prevention | versus placebo or control No demonstrated result for efficacy vorapaxar inferior to placebo (on top aspirin) in terms of major haemorrhage requiring admission to hospital in TRA-2P TIMI 50, 2012 (secondary prevention patients) vorapaxar inferior to placebo (on top aspirin) in terms of Major hemorrhage in TRA-2P TIMI 50, 2012 (secondary prevention patients) vorapaxar inferior to placebo (on top aspirin) in terms of Intracranial haemorrhage in TRA-2P TIMI 50, 2012 (secondary prevention patients) vorapaxar inferior to placebo (on top aspirin) in terms of Major hemorrhage in TRA-2P TIMI 50 (MI subgroup), 2012 (secondary prevention patients) | 3 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
TRA-2P TIMI 50, 2012 | vorapaxar vs placebo (on top aspirin) | myocardial infarction 0.84 [0.75; 0.93] all vascular event 0.87 [0.80; 0.94] CV death, MI, stroke 0.87 [0.81; 0.95] | major haemorrhage requiring admission to hospital 1.42 [1.32; 1.52] Major hemorrhage 1.45 [1.21; 1.73] Intracranial haemorrhage 1.92 [1.38; 2.68] | All cause mortality 0.96 [0.85; 1.07] cardiovascular death 0.89 [0.76; 1.05] fatal bleeding 1.45 [0.82; 2.56] Stroke (any) 0.97 [0.83; 1.13] | TRA-2P TIMI 50 (no prior stroke sub group), 2012 | vorapaxar vs placebo (on top aspirin) | all vascular event 0.84 [0.76; 0.93] | | | TRA-2P TIMI 50 (MI subgroup), 2012 | vorapaxar vs placebo (on top aspirin) | all vascular event 0.81 [0.73; 0.90] | Major hemorrhage 1.29 [1.02; 1.63] | All cause mortality 0.93 [0.79; 1.09] fatal bleeding 1.56 [0.45; 5.41] Intracranial haemorrhage 1.54 [0.54; 4.34] fatal hemorrhagic stroke 1.53 [0.95; 2.46] net benefit 0.92 [0.36; 2.33] |
Trial | Treatments | Patients | Method |
---|
TRA-2P TIMI 50, 2012 | vorapaxar (SCH 530348) 2.5-mg daily (n=13225) vs. placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel) (n=13244) | patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease) trial was discontinued in patients who experienced a stroke. The study drug will be continued in patients with previous MI or peripheral disease | double-blind Parallel groups Sample size: 13225/13244 Primary endpoint: CV death, MI, stroke, urgent revascularization FU duration: 2.5 y (median) | TRA-2P TIMI 50 (no prior stroke sub group), 2012 | vorapaxar (SCH 530348) 2.5-mg daily
(n=20699) vs. placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)
(n=0)
| patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease), sub group of patient with no prior stroke
trial was discontinued in patients who experienced a stroke. The study drug will be continued in patients with previous MI or peripheral disease
| double-blind Parallel groups Sample size: 20699/0 Primary endpoint: CV death, MI, stroke, urgent revascularization FU duration: 2.5 y (median)
| TRA-2P TIMI 50 (MI subgroup), 2012 | vorapaxar (SCH 530348) 2.5-mg daily
(n=8898) vs. placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel)
(n=8881)
| prespecified subgroup of patients with a qualifying myocardial infarction among the overall population of patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease)
trial was discontinued in patients who experienced a stroke. The study drug will be continued in patients with previous MI or peripheral disease
| double-blind Parallel groups Sample size: 8898/8881 Primary endpoint: CV death, MI, stroke, urgent revascularization FU duration: 2.5 y (median)
|
|
diabetes type 2 | aspirin | not classified | versus placebo or control No demonstrated result for efficacy aspirin inferior to placebo in terms of non fatal MI in DAMAD, 1989 | 7 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
POPADAD aspirin, 2008 | aspirin vs placebo | | | All cause mortality 0.93 [0.72; 1.21] CHD death 1.35 [0.82; 2.21] CHD events (fatal and non fatal) 1.10 [0.83; 1.45] CV death 1.23 [0.80; 1.89] fatal MI 1.35 [0.82; 2.21] fatal stroke 0.89 [0.35; 2.29] non fatal MI 0.98 [0.69; 1.40] stroke (fatal and non fatal) 0.74 [0.49; 1.12] CV events (fatal and non fatal) 0.99 [0.79; 1.25] peripheral artery disease 0.91 [0.70; 1.17] stable angina 0.90 [0.66; 1.22] | JPAD, 2008 | aspirin vs no treatment | CV death 0.10 [0.01; 0.79] | | CHD death 0.00 [0.00; NaN] CHD events (fatal and non fatal) 0.81 [0.50; 1.32] fatal MI 0.00 [0.00; NaN] fatal stroke 0.20 [0.02; 1.73] non fatal MI 1.35 [0.57; 3.19] stroke (fatal and non fatal) 0.89 [0.54; 1.46] CV events (fatal and non fatal) 0.80 [0.59; 1.09] peripheral artery disease 0.64 [0.25; 1.66] stable angina 1.10 [0.49; 2.49] unstable angina 0.40 [0.13; 1.29] | DAMAD, 1989 | aspirin vs placebo | | non fatal MI 4.20 [1.10; 16.10] | All cause mortality 0.49 [0.13; 1.95] CV death 0.49 [0.10; 2.42] CV events (fatal and non fatal) 1.48 [0.68; 3.22] | ETDRS, 1992 | aspirin vs placebo | CHD events (fatal and non fatal) 0.85 [0.73; 1.00] | | All cause mortality 0.93 [0.81; 1.06] CV death 0.92 [0.79; 1.07] non fatal MI 0.78 [0.54; 1.11] stroke (fatal and non fatal) 1.18 [0.88; 1.58] CV events (fatal and non fatal) 0.95 [0.83; 1.07] | PHS (diabetics sub group), 1989 | aspirin vs placebo | CHD events (fatal and non fatal) 0.40 [0.20; 0.79] | | | PPP (diabetics sub group), 2003 | aspirin vs no treatment | | | All cause mortality 1.23 [0.69; 2.19] CHD events (fatal and non fatal) 0.49 [0.17; 1.43] CV death 1.23 [0.49; 3.10] revascularization procedure 0.79 [0.31; 1.98] stroke (fatal and non fatal) 0.89 [0.36; 2.17] all MI 0.49 [0.17; 1.43] CV events (fatal and non fatal) 0.90 [0.50; 1.62] peripheral artery disease 0.83 [0.38; 1.85] stable angina 0.80 [0.39; 1.65] | WHS (diabetics sub group), 2005 | aspirin vs placebo | stroke (fatal and non fatal) 0.48 [0.26; 0.88] | | CHD events (fatal and non fatal) 1.50 [0.91; 2.47] all MI 1.50 [0.91; 2.47] CV events (fatal and non fatal) 0.93 [0.67; 1.31] |
Trial | Treatments | Patients | Method |
---|
POPADAD aspirin, 2008 | aspirin 100mg daily (n=638) vs. placebo (n=638) factoral design with antioxidant capsule | patients with diabetes mellitus and asymptomatic peripheral arterial disease | double blind Factorial plan Sample size: 638/638 Primary endpoint: Cv events; CHD death+stroke FU duration: nov 1997 - jul 2001 | JPAD, 2008 | low-dose aspirin (81 or 100 mg per day) (n=1262) vs. no aspirin (n=1277) | patients with type 2 diabetes without a history of atherosclerotic disease | open Parallel groups Sample size: 1262/1277 Primary endpoint: atherosclerotic events FU duration: 4.37 y median | DAMAD, 1989 | aspirin alone (330 mg 3 times daily) or in combination with dipyridamole (75 mg 3 times daily) (n=318) vs. placebo (n=157) | patients with early diabetic retinopathy | double blind Parallel groups Sample size: 318/157 Primary endpoint: number of microaneurysms FU duration: 3 y | ETDRS, 1992 | aspirin 650mg once daily (n=1856) vs. placebo (n=1855) | patients with diabetes mellitus (Type I or II) | double blind Parallel groups Sample size: 1856/1855 Primary endpoint: Mortality from all causes FU duration: 60 months | PHS (diabetics sub group), 1989 | aspirin 325 mg every other day (n=275) vs. placebo (n=258) | healthy men (diabetic sub group of patients enrolled if PHS) | double blind Factorial plan Sample size: 275/258 Primary endpoint: cardiovascular mortality FU duration: 5 y | PPP (diabetics sub group), 2003 | aspirin 100mg daily (n=519) vs. control (n=512) factorial design evaluating aspirin and vitamin E | men and women with diabetes and without a previous cardiovascular event aged >50 with >=1 risk factors for cardiovascular disease - sub group of diabetic patients Initialy, PPP enrolled 4784 patients of whom 1031 had diabetes | open Factorial plan Sample size: 519/512 Primary endpoint: CV events FU duration: 3.6 y sub group study | WHS (diabetics sub group), 2005 | aspirin 100mg on alternate days (n=514) vs. placebo (n=513) factorial design of aspirin and vitamin E | healthy women 45 years of age or older - diabetics sub groups trial enrolled 39876 patients of whom 1027 had diabetes (2.6%) | double blind Parallel groups Sample size: 514/513 Primary endpoint: cardiovascular event FU duration: 10.1 y sub group |
|
diabetes type 2 | picotamide | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Cocozza, 1995 | picotamide vs placebo | | | CV death 0.00 [0.00; NaN] non fatal MI 0.00 [0.00; NaN] CV events (fatal and non fatal) 0.00 [0.00; NaN] |
Trial | Treatments | Patients | Method |
---|
Cocozza, 1995 | picotamide 300 mg TID (n=25) vs. placebo (n=25) | normotensive diabetic patients with asymptomatic mild or moderate nonstenotic (< 50%) carotid atherosclerotic lesions and negative history of cerebrovascular ischemic events | double blind Parallel groups Sample size: 25/25 Primary endpoint: not unique (carotid atherosclerotic lesions) FU duration: 24 months |
|
diabetes type 2 | sulfinpyrazone | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Dutch, 1980 | sulfinyrazone vs placebo | | | All cause mortality ∞ [NaN; ∞] CV death ∞ [NaN; ∞] non fatal MI 1.00 [0.05; 18.57] CV events (fatal and non fatal) 2.07 [0.41; 10.46] |
Trial | Treatments | Patients | Method |
---|
Dutch, 1980 | sulfinyrazone (n=30) vs. (n=31) | | Parallel groups Sample size: 30/31 Primary endpoint: FU duration: 32 months |
|
diabetes type 2 | ticlopidine | not classified | versus placebo or control No demonstrated result for efficacy | 5 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Birmingham-A, 1979 | ticlopidine vs placebo | | | All cause mortality NaN [NaN; NaN] CV death NaN [NaN; NaN] non fatal MI 0.00 [0.00; NaN] CV events (fatal and non fatal) 0.00 [0.00; NaN] | London diabetes, 1983 | ticlopidine vs placebo | | | All cause mortality 1.05 [0.07; 16.24] CV death 1.05 [0.07; 16.24] non fatal MI NaN [NaN; NaN] CV events (fatal and non fatal) 0.53 [0.05; 5.57] | TIMAD, 1984 | ticlopidine vs placebo | | | All cause mortality 0.73 [0.17; 3.24] CV death 0.49 [0.04; 5.35] non fatal MI 0.33 [0.03; 3.84] CV events (fatal and non fatal) 0.56 [0.17; 1.88] | BTRS, 1992 | ticlopidine vs placebo | | | All cause mortality NaN [NaN; NaN] CV death NaN [NaN; NaN] non fatal MI 0.00 [0.00; NaN] CV events (fatal and non fatal) 0.00 [0.00; NaN] | Nyberg, 1984 | ticlopidine vs placebo | | | All cause mortality ∞ [NaN; ∞] CV death ∞ [NaN; ∞] non fatal MI NaN [NaN; NaN] CV events (fatal and non fatal) ∞ [NaN; ∞] |
Trial | Treatments | Patients | Method |
---|
Birmingham-A, 1979 | ticlopidine 100, 250, 500 mg (n=20) vs. (n=8) | | Parallel groups Sample size: 20/8 Primary endpoint: FU duration: 2 months | London diabetes, 1983 | ticlopidine 500mg (n=38) vs. (n=40) | | Parallel groups Sample size: 38/40 Primary endpoint: FU duration: 12 months | TIMAD, 1984 | ticlopidine 500mg (n=220) vs. (n=215) | | Parallel groups Sample size: 220/215 Primary endpoint: FU duration: 32m | BTRS, 1992 | ticlopidine 500mg/d (n=49) vs. placebo (n=51) | insulin-treated diabetics with background retinopathy | double blind Parallel groups Sample size: 49/51 Primary endpoint: evolution of retinopathy FU duration: 48 months | Nyberg, 1984 | ticlopidine 500mg daily (n=12) vs. placebo (n=11) | insulin dependent diabetes complicated by nephropathy | double blind Parallel groups Sample size: 12/11 Primary endpoint: FU duration: 12 months |
|
hypertension | aspirin | primary prevention | versus placebo or control No demonstrated result for efficacy aspirin inferior to placebo in terms of Major extracranial bleed in HOT, 1998 (primary prevention patients) aspirin inferior to placebo in terms of Gastrointestinal Bleeding in HOT, 1998 (primary prevention patients) aspirin inferior to placebo in terms of Major gastrointestinal bleeding in HOT, 1998 (primary prevention patients) | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
HOT, 1998 | aspirin vs placebo | total coronary heart disease events 0.65 [0.49; 0.85] non fatal MI 0.60 [0.44; 0.80] myocardial infarction (fatal and non fatal) 0.65 [0.49; 0.85] CV events (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular cause) 0.86 [0.74; 0.99] | Major extracranial bleed 1.93 [1.43; 2.62] Gastrointestinal Bleeding 1.94 [1.41; 2.69] Major gastrointestinal bleeding 2.08 [1.41; 3.07] | all-cause mortality 0.93 [0.79; 1.09] coronary heart disease mortality 1.00 [0.48; 2.09] Cv death 0.95 [0.75; 1.20] Hemorrhagic Stroke and Intracranial Hemorrhage 0.93 [0.45; 1.93] fatal bleeding 0.87 [0.32; 2.41] fatal and nonfatal stroke 0.99 [0.79; 1.24] |
Trial | Treatments | Patients | Method |
---|
HOT, 1998 | aspirin 75 mg daily (n=9399) vs. placebo (n=9391) factorial design with as 2nd factor the comparison of 3 BP targets | patients aged 50-80 with hypertension and diastolic blood pressure between 100 mmHG and 115 mmHG | Double blind Factorial plan Sample size: 9399/9391 Primary endpoint: non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death FU duration: mean 3.8 y (range 3.3-4.9y) |
|
percutaneous coronary intervention | cilostazol | not classified | versus antiplatelet drugs No demonstrated result for efficacy | 7 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Kozuma, 2001 | cilostazol + aspirin vs ticlopidine + aspirin | | | MACE 0.00 [0.00; NaN] | Ochiai, 1999 | cilostazol + aspirin vs ticlopidine + aspirin | | | MACE 1.00 [0.15; 6.55] | Park, 1999 | cilostazol + aspirin vs ticlopidine + aspirin | | | MACE 1.97 [0.18; 21.56] | Yoon, 1999 | cilostazol + aspirin vs ticlopidine + aspirin | | | MACE 0.68 [0.11; 3.99] | Kamishirado, 2002 | cilostazol + aspirin vs ticlopidine + aspirin | | | MACE 0.00 [0.00; NaN] | Sekiya, 1998 | cilostazol + aspirin vs aspirin | | | MACE 0.00 [0.00; NaN] | Kunishima, 1997 | cilostazol vs aspirin | | | MACE 0.00 [0.00; NaN] |
Trial | Treatments | Patients | Method |
---|
Kozuma, 2001 | Cilostazol 200 mg qD x6 mos Aspirin 81–162 mg qD (n=62) vs. Ticlopidine 200 mg qD x6 mos Aspirin 81–162 mg qD (n=63) | | Sample size: 62/63 Primary endpoint: FU duration: | Ochiai, 1999 | Cilostazol 100 mg BID x6 mos Aspirin 81 mg TID (n=25) vs. Ticlopidine 100 mg BID x1 mo Aspirin 81 mg TID (n=25) | | Sample size: 25/25 Primary endpoint: FU duration: | Park, 1999 | Cilostazol 100 mg BID x6 mos Aspirin 200 mg qD (n=247) vs. Ticlopidine 250 mg BID x4 wks Aspirin 200 mg qD (n=243) | | Sample size: 247/243 Primary endpoint: FU duration: | Yoon, 1999 | Cilostazol 100 mg BID x30 days Aspirin 100 mg qD (n=147) vs. Ticlopidine 250 mg BID x30 days Aspirin 100 mg qD (n=149) | | Sample size: 147/149 Primary endpoint: FU duration: | Kamishirado, 2002 | Cilostazol 200 mg qD x6 mos Aspirin 81 mg qD (n=65) vs. Ticlopidine 200 mg qD x6 mos Aspirin 81 mg qD (n=65) | | Sample size: 65/65 Primary endpoint: FU duration: | Sekiya, 1998 | Cilostazol 200 mg qD x6mos Aspirin 81 mg qD (n=63) vs. Coumadin unspecified regimen Aspirin 81 mg qD (n=63) | | Sample size: 63/63 Primary endpoint: FU duration: | Kunishima, 1997 | Cilostazol 200 mg qD unspecified durationg qD (n=30) vs. Aspirin 81 mg qD (n=40) | | Sample size: 30/40 Primary endpoint: FU duration: |
|
percutaneous coronary intervention | clopidogrel | not classified | versus No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
REAL-LATE, ZEST-LATE, 2010 | clopidogrel+aspirin vs aspirin | | | all cause death 1.52 [0.76; 3.05] major bleeding 2.97 [0.31; 28.51] stroke 2.23 [0.69; 7.21] MI 1.41 [0.54; 3.70] definite stent thrombosis 1.24 [0.33; 4.60] |
Trial | Treatments | Patients | Method |
---|
REAL-LATE, ZEST-LATE, 2010 | clopidogrel plus aspirin (n=1357) vs. aspirin alone (n=1344) | patients who had received drugeluting
stents and had been free of major adverse cardiac or cerebrovascular events
and major bleeding for a period of at least 12 months | open Parallel groups Sample size: 1357/1344 Primary endpoint: CV death, MI FU duration: 19.2 months |
|
percutaneous coronary intervention | clopidogrel | not classified | versus antiplatelet drugs No demonstrated result for efficacy | 4 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
Müller, 2000 | clopidogrel + aspirin vs ticlopidine + aspirin | | | MACE 1.78 [0.67; 4.76] | CLASSICS, 2000 | clopidogrel + aspirin vs ticlopidine + aspirin | | | MACE 1.31 [0.30; 5.83] | TOPPS, 2001 | clopidogrel + aspirin vs ticlopidine + aspirin | | | MACE 0.84 [0.46; 1.51] | Piamsomboon, 2001 | clopidogrel + aspirin vs ticlopidine + aspirin | | | MACE 0.00 [0.00; NaN] |
Trial | Treatments | Patients | Method |
---|
Müller, 2000 | Clopidogrel 75 mg qD x4 wks Aspirin 100 mg qD (n=355) vs. Ticlopidine 250 mg BID x4 wks Aspirin 100 mg qD (n=345) | | Sample size: 355/345 Primary endpoint: FU duration: | CLASSICS, 2000 | Clopidogrel 300mg x1, 75 mg qD x4 wks Aspirin 325 mg qDypñ ·` (n=345) vs. Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD (n=340) | | Sample size: 345/340 Primary endpoint: FU duration: | TOPPS, 2001 | Clopidogrel 300 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD (n=494) vs. Ticlopidine 500 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD (n=522) | | Sample size: 494/522 Primary endpoint: FU duration: | Piamsomboon, 2001 | Clopidogrel 300 mg x1, 75 mg qD x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD (n=37) vs. Ticlopidine 250 mg po BID x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD (n=31) | | Sample size: 37/31 Primary endpoint: FU duration: |
|
percutaneous coronary intervention | clopidogrel | not classified | versus standard clopidogrel No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
GRAVITAS, 2011 | high-dose clopidogrel vs normal-dose clopidogrel | | | all cause death 0.70 [0.27; 1.83] Cardiovascular death 0.37 [0.10; 1.40] MI 1.11 [0.59; 2.08] any bleeding 1.17 [0.93; 1.49] GUSTO severe/moderate bleeding 0.60 [0.32; 1.13] Cardiovascular death/MI/stent thrombosis 1.01 [0.58; 1.76] definite stent thrombosis 0.62 [0.20; 1.90] |
Trial | Treatments | Patients | Method |
---|
GRAVITAS, 2011 | High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) (n=1109) vs. regular clopidogrel dose (n=1105) | patients receiving drug-eluting stents with high residual platelet activity (PRU>=230) on the regular clopidogrel dose (platelet-function tests with the VerifyNow assay 12 to 24 hours after PCI) | open Parallel groups Sample size: 1109/1105 Primary endpoint: Cardiovascular death/MI/stent thrombosis FU duration: 6 months |
|
percutaneous coronary intervention | ticlopidine | not classified | versus anticoagulant + antiplatelet No demonstrated result for efficacy | 5 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
FANTASTIC, 1998 | ticlopidine + aspirin vs coumadin + aspirin | | | MACE 0.70 [0.36; 1.36] | ISAR, 1996 | ticlopidine + aspirin vs coumadin + aspirin | MACE 0.25 [0.09; 0.75] | | | Foussas, 2000 | ticlopidine + aspirin vs coumadin + aspirin | MACE 0.31 [0.15; 0.63] | | | MATTIS, 1998 | ticlopidine + aspirin vs coumadin + aspirin | | | MACE 0.51 [0.25; 1.07] | STARS (vs coumadin+asp), 1998 | ticlopidine + aspirin vs coumadin + aspirin | MACE 0.20 [0.06; 0.69] | | |
Trial | Treatments | Patients | Method |
---|
FANTASTIC, 1998 | Ticlopidine 250 mg BID 6 wks Aspirin 100–325 mg qD (n=243) vs. Coumadin INR† 2.5–3.0 6 wks Aspirin 100–325 mg qD/pj (n=230) | | Sample size: 243/230 Primary endpoint: FU duration: | ISAR, 1996 | Ticlopidine 250 mg BID 4 wks Aspirin 100 mg BIDage/pj (n=257) vs. Coumadin INR 3.5–4.5 4 wks Aspirin 100 mg BID (n=260) | | Sample size: 257/260 Primary endpoint: FU duration: | Foussas, 2000 | Ticlopidine 500mg qD 1 mo Aspirin 325 mg qD (n=203) vs. Coumadin INR 2–3 x4 wks Aspirin 325 mg qDg BID (n=201) | | Sample size: 203/201 Primary endpoint: FU duration: | MATTIS, 1998 | Ticlopidine 250 mg BID 30 days Aspirin 250 mg qD (n=177) vs. Coumadin INR 2.5–3.0 x30 days Aspirin 250 mg qDg qD/pj (n=173) | | Sample size: 177/173 Primary endpoint: FU duration: | STARS (vs coumadin+asp), 1998 | Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD (n=546) vs. Coumadin INR 2–2.5 x4 wks Aspirin 325 mg qDBID (n=550) | | Sample size: 546/550 Primary endpoint: FU duration: |
|
percutaneous coronary intervention | ticlopidine | not classified | versus antiplatelet drugs No demonstrated result for efficacy | 2 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
STARS (vs aspirin), 1998 | ticlopidine + aspirin vs aspirin | MACE 0.15 [0.05; 0.51] | | | Hall, 1996 | ticlopidine + aspirin vs aspirin | | | MACE 1.98 [0.24; 16.40] |
Trial | Treatments | Patients | Method |
---|
STARS (vs aspirin), 1998 | Ticlopidine 250 mg BID 4 wks Aspirin 325 mg qDDage/pj (n=546) vs. Aspirin 325 mg qD (n=557) | | Sample size: 546/557 Primary endpoint: FU duration: | Hall, 1996 | Ticlopidine 250 mg BID 1 mo Aspirin 325 mg qD 5 days (n=13) vs. Aspirin 325 mg qD (n=103) | | Sample size: 13/103 Primary endpoint: FU duration: |
|
peripheral vascular diseases | aspirin | not classified | versus placebo or control No demonstrated result for efficacy | 5 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| aspirin vs placebo | | | | | aspirin vs placebo | | | | | aspirin vs placebo | | | | | aspirin vs placebo | | | | CLIPS, 2007 | aspirin vs placebo | Evénements vasculaires 0.42 [0.22; 0.80] IDM totaux 0.18 [0.04; 0.79] | | Mortalité totale 1.71 [0.51; 5.75] IDM fatal 0.98 [0.14; 6.87] Mortalité vasculaire 1.22 [0.33; 4.48] AVC fatal 1.96 [0.18; 21.39] AVC non fatal 0.33 [0.07; 1.59] IDM non fatal 0.00 [0.00; NaN] |
Trial | Treatments | Patients | Method |
---|
Schoop, 1983 | groupe 1 : Aspirine 990 mg / j
(pour mémoire : groupe 2 : Aspirine 990 mg / j + dipyridamole 225 mg/j) (n=100) vs. Placebo (n=100) Données isuues de la méta-analyse ATC | AOMI stade non précisé | double blind Parallel groups Sample size: 100/100 Primary endpoint: Progression de l’athérosclérose FU duration: <5 y | Hess, 1985 | groupe 1 : Aspirine 330 mg / j
(pour mémoire : groupe 2 : Aspirine 330 mg / j + dipyridamole 75 mg / j) (n=80) vs. Placebo (n=80) | AOMI stade non précisé | single blind Parallel groups Sample size: 80/80 Primary endpoint: Score de progression de l’athérosclérose FU duration: | Munich A, 1975 | Aspirine: 1500 mg / jour (n=92) vs. Placebo (n=84) | Données non disponibles | double blind Parallel groups Sample size: 92/84 Primary endpoint: FU duration: | Munich B, 1975 | Aspirine 1500 mg / jour pendant 24 mois (n=42) vs. Placebo (n=40) | NA | double blind Parallel groups Sample size: 42/40 Primary endpoint: FU duration: | CLIPS, 2007 | oral aspirin 100 mg daily (n=185) vs. placebo (n=181) factorial design with 2nd factor antioxidant vitamins (600mg vit E, 250mg vit C and 20mg beta-caroteen daily) vs placebo | outpatients with stage I-II PAD documented by angiography or ultrasound, with ankle/brachial index <0.85 or toe index <0.6 | double blind Factorial plan Sample size: 185/181 Primary endpoint: cardiovascular death, myocardial infarction, stroke, critical leg ischaemia FU duration: 20.7 months mean |
|
peripheral vascular diseases | clopidogrel | not classified | versus aspirin No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
CAPRIE (PAD subgroup), 1996 | clopidogrel vs aspirin | IDM fatal 0.62 [0.44; 0.88] IDM totaux 0.63 [0.47; 0.85] | | Mortalité totale 0.81 [0.63; 1.06] AVC fatal 0.95 [0.69; 1.31] AVC non fatal 1.38 [0.55; 3.42] IDM non fatal 0.67 [0.37; 1.21] |
Trial | Treatments | Patients | Method |
---|
CAPRIE (PAD subgroup), 1996 | Clopidogrel 75 mg (n=3223) vs. Aspirine 325 mg (n=3229) | patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease Effectifs correspondant à la strate AOMI | double blind Parallel groups Sample size: 3223/3229 Primary endpoint: Critère composite FU duration: 1.91 y |
|
peripheral vascular diseases | dipyridamol | not classified | versus placebo or control No demonstrated result for efficacy | 3 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| aspirin + dipyridamol vs placebo | | | | | aspirin + dipyridamol vs placebo | | | | | aspirin + dipyridamol vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
Hess (2), 1985 | Aspirine Dipyridamole 330 mg / j 225 mg / j (n=80) vs. Placebo (n=80) | patients with occlusive arterial disease in the lower extremities | double blind Parallel groups Sample size: 80/80 Primary endpoint: Score de progression de l’athérosclérose FU duration: | Schoop (2), 1983 | Aspirine Dipyridamole 990 mg / j 225 mg /j (n=100) vs. Placebo (n=100) | AOMI stade non précisé | double blind Parallel groups Sample size: 100/100 Primary endpoint: Progression de l’athérosclérose FU duration: | VA study, 1986 | Aspirine + Dipyridamole 975 mg / j 225 mg /j (n=110) vs. Placebo (n=121) | non-insulin-dependent diabetic men with either a recent amputation for gangrene or active gangrene | double blind Parallel groups Sample size: 110/121 Primary endpoint: Mortalité due à une pathologie vasculaire athérosclérotique ou amputation pour gangrène au membre op FU duration: 46 months |
|
peripheral vascular diseases | ketanserine | not classified | versus placebo or control No demonstrated result for efficacy | 3 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| ketanserine vs placebo | | | | | ketanserine vs placebo | | | | | ketanserine vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
PACK, 1996 | Ketanserin 40 mg / j pdt 1 mois 80 mg / j ensuite (n=1930) vs. Placebo (n=1969) | patients over 40 years old who had had documented intermittent claudication for at least two months and in whom the ratio of systolic blood pressure in the ankle to that in the arm was less than or equal to 0.85 in both arteries of at least one foot | double blind Parallel groups Sample size: 1930/1969 Primary endpoint: IDM, AVC majeur, amputation au dessus de la cheville pour des raisons autres que tumorales ou trauma FU duration: 1 y | Walden, 1991 | Ketanserin 60 mg / j pdt 1 mois 120 mg / j ensuite (n=17) vs. Placebo (n=18) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: 17/18 Primary endpoint: Périmètre de marche FU duration: 15 months | Thulesius, 1987 | Ketanserin 60 mg / j pdt 2 semaines 120 mg / j ensuite (n=79) vs. Placebo (n=86) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: 79/86 Primary endpoint: Périmètre de marche FU duration: 6 months |
|
peripheral vascular diseases | picotamide | not classified | versus placebo or control No demonstrated result for efficacy | 3 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| picotamide vs placebo | | | | | picotamide vs placebo | | | | | picotamide vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
ADEP, 1993 | Picotamide 600 mg / j (n=1150) vs. Placebo (n=1154) | patients with peripheral obstructive arterial disease (stade II+) | double blind Parallel groups Sample size: 1150/1154 Primary endpoint: Mortalité vasculaire et non vasculaire, IDM fatal ou non, AVC fatal ou non, amputation au dessus de FU duration: 18 months | Neirotti, 1994 | Picotamide 900 mg / j (n=10) vs. Placebo (n=10) | patients with peripheral arterial disease (PAD) at functional stage 2 of the Fontaine classification and with intermittent claudication for at least six months | double blind Parallel groups Sample size: 10/10 Primary endpoint: Paramètres hémodynamiques, de coagulation, d’activité plaquettaire FU duration: 18 months | Coto, 1989 | Picotamide 900 mg / j (n=20) vs. Placebo (n=20) | patients with peripheral occlusive arterial disease of the lower limbs at functional stage II of the Fontaine classification | double blind Parallel groups Sample size: 20/20 Primary endpoint: Périmètres de marche, paramètres sanguins FU duration: 6 months |
|
peripheral vascular diseases | suloctidil | not classified | versus placebo or control No demonstrated result for efficacy | 4 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| suloctidil vs placebo | | | | | suloctidil vs placebo | | | | | suloctidil vs placebo | | | | | suloctidil vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
Adriaensen, 1976 | Suloctidil 200 mg / j (n=15) vs. Placebo (n=15) | patients suffering from intermittent claudication ( stade II) | double blind Parallel groups Sample size: 15/15 Primary endpoint: Périmètre de marche FU duration: 2 months | Verhaeghe, 1981 | Suloctidil 200 mg / j (n=-9) vs. Placebo (n=-9) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: -9/-9 Primary endpoint: Périmètre de marche FU duration: 6 months | Jones, 1982 | Suloctidil 300 mg / j (n=18) vs. Placebo (n=22) | patients suffering from intermittent claudication (stade II) | double blind Parallel groups Sample size: 18/22 Primary endpoint: Périmètre de marche, pression à la cheville, flux sanguin musculaire FU duration: 6 months | Holm, 1984 | Suloctidil 300 mg / j (n=20) vs. Placebo (n=20) | AOMI stade II | double blind Parallel groups Sample size: 20/20 Primary endpoint: Périmètre de marche, pression à la cheville, flux sanguin musculaire FU duration: 2.75 y |
|
peripheral vascular diseases | ticagrelor | not classified | versus No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
EUCLID, 2016 | ticagrelor vs clopidogrel | | | |
Trial | Treatments | Patients | Method |
---|
EUCLID, 2016 | ticagrelor (90 mg twice daily) (n=-9) vs. clopidogrel (75 mg once daily) (n=-9) | patients with symptomatic peripheral artery disease | Sample size: -9/-9 Primary endpoint: FU duration: 30 months (median) |
|
peripheral vascular diseases | ticlopidine | not classified | versus placebo or control No demonstrated result for efficacy | 11 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | | | ticlopidine vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
EMATAP, 1993 | Ticlopidine 500 mg/j (n=304) vs. Placebo (n=311) | AOMI stade non précisé | double blind Parallel groups Sample size: 304/311 Primary endpoint: Mortalité subite, IDM, AVC, intervention chirurgicale liée à une aggravation clinique FU duration: | Katsumara, 1982 | Ticlopidine 500 mg/j (n=93) vs. Placebo (n=100) | patients with ischemic ulcers due to chronic arterial occlusion | double blind Parallel groups Sample size: 93/100 Primary endpoint: Taille / cicatrisation des ulcères FU duration: 6 semaines | Aukland, 1982 | Ticlopidine 500 mg/j (n=33) vs. Placebo (n=32) | men with atherosclerotic intermittent claudication and haemorheological abnormalities | double blind Parallel groups Sample size: 33/32 Primary endpoint: Périmètre de marche, pressionsystolique à la cheville FU duration: 1 y | Stiegler, 1984 | Ticlopidine 500 mg/j (n=57) vs. Placebo (n=57) | AOMI stade II | double blind Parallel groups Sample size: 57/57 Primary endpoint: Score de progression de l’athérosclérose FU duration: | Ellis, 1986 | Ticlopidine 500 mg/j (n=100) vs. Placebo (n=103) | AOMI stade II | double blind Parallel groups Sample size: 100/103 Primary endpoint: Périmètre de marche FU duration: 6 months | Cloarec, 1986 | Ticlopidine 500 mg/j (n=66) vs. Placebo (n=66) | AOMI stade non précisé | double blind Parallel groups Sample size: 66/66 Primary endpoint: Périmètre de marche FU duration: 1 y | Arcan, 1988 | Ticlopidine 500 mg/j (n=83) vs. Placebo (n=86) | patients with chronic intermittent claudication due to obstructive peripheral vascular disease (stade II) | double blind Parallel groups Sample size: 83/86 Primary endpoint: Périmètre de marche FU duration: 6 months randomisation centralisée | Balsano, 1989 | Ticlopidine 500 mg/j (n=76) vs. Placebo (n=75) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: 76/75 Primary endpoint: Périmètre de marche FU duration: 21 months | STIMS, 1990 | Ticlopidine 500 mg/j (n=346) vs. Placebo (n=341) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: 346/341 Primary endpoint: IDM, AVC, AIT FU duration: 5.6 y | Hurlow, 1980 | Ticlopidine : 100 -500 mg / jour pendant 2 mois. (n=30) vs. Placebo (n=30) | Données non disponibles | double blind Parallel groups Sample size: 30/30 Primary endpoint: FU duration: | Krause, 1980 | Ticlopidine : 500 mg pendant 4 mois (n=19) vs. Placebo (n=19) | Données non disponibles | double blind Parallel groups Sample size: 19/19 Primary endpoint: FU duration: |
|
peripheral vascular diseases | various | not classified | versus placebo or control No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| cloricromene vs placebo | | | |
Trial | Treatments | Patients | Method |
---|
CRAMPS, 2000 | Cloricromène : 100 mg, 2 fois / jour / voie orale + aspirine : 160 mg / jour pendant 6 mois . (n=81) vs. placebo + aspirine: 160 mg/ jour pendant 6 mois. (n=78) | Stade de la maladie : II, pendant 3.1 années d'ancienneté en moyenne dans les 2 groupes
| double blind Parallel groups Sample size: 81/78 Primary endpoint: périmètre de marche ( maximal, sans douleur) FU duration: 6 months Tous les pts ont été admis dans une période de run-in de 3 semaines en simple aveugle : avec prise d'1 cp de placebo, 2 fois / jour, afin d'évaluer leur éligiblité dans la période en double aveugle de l'essai.
Randomisation centralisée |
|
post myocardial infarction | aspirin | not classified | versus placebo or control No demonstrated result for efficacy | 8 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
CDPA, 1976 | aspirin vs placebo | | | Total mortality 0.70 [0.48; 1.01] Cardiovascular death 0.70 [0.47; 1.02] Non-fatal MI 0.89 [0.54; 1.46] | Cardiff I, 1974 | aspirin vs placebo | | | Total mortality 0.74 [0.52; 1.05] | Cardiff II, 1979 | aspirin vs placebo | | | Total mortality 0.83 [0.65; 1.05] | Vogel, 1979 | aspirin vs placebo | Cardiovascular death 0.50 [0.27; 0.92] Fatal MI 0.38 [0.17; 0.85] Non-fatal MI 0.47 [0.29; 0.75] | | Total mortality 0.68 [0.44; 1.05] | AMIS, 1980 | aspirin vs placebo | Non-fatal MI 0.78 [0.63; 0.96] | | Total mortality 1.11 [0.94; 1.32] | GAMIS, 1980 | aspirin vs placebo | | | Total mortality 0.82 [0.51; 1.34] Fatal MI 0.49 [0.17; 1.41] Non-fatal MI 0.71 [0.33; 1.53] | PARIS, 1980 | aspirin vs placebo | | | Total mortality 0.82 [0.59; 1.13] Cardiovascular death 0.82 [0.58; 1.17] Non-fatal MI 0.70 [0.48; 1.03] | JAMIS, 1999 | aspirin vs placebo | Non-fatal MI 0.27 [0.10; 0.72] | | Total mortality 1.18 [0.45; 3.12] Cardiovascular death 1.10 [0.34; 3.57] |
Trial | Treatments | Patients | Method |
---|
CDPA, 1976 | Aspirin (324 mg) 3x/d (n=758) vs. Placebo (n=771) | MI survivors | Double blind Parallel groups Sample size: 758/771 Primary endpoint: No primary outcome clearly defined FU duration: 1.83 y | Cardiff I, 1974 | Aspirin (300 mg) 1x/d (n=615) vs. Placebo (n=624) | MI survivors | Double blind Parallel groups Sample size: 615/624 Primary endpoint: Total mortality FU duration: 2 years | Cardiff II, 1979 | Aspirin (300 mg) 3x/d for one year (n=832) vs. Placebo (n=850) | patients with myocardial infarction | Double blind Parallel groups Sample size: 832/850 Primary endpoint: Total mortality FU duration: 1 y | Vogel, 1979 | Aspirin (1.5 g daily) on an average period of 22 months
(n=672) vs. Placebo
(n=668) | | Double blind Parallel groups Sample size: 672/668 Primary endpoint: Death or reinfraction FU duration: 1.75 y (mean) | AMIS, 1980 | Aspirin (500 mg) 2x/d for at least 3 years (n=2267) vs. Placebo (n=2257) | men and women who had had a documented myocardial infarction | Double blind Parallel groups Sample size: 2267/2257 Primary endpoint: Total mortality FU duration: > 3 y | GAMIS, 1980 | Aspirin (500 mg) 3x/d for 2 years (n=317) vs. Placebo (n=309) | patients who had survived a myocardial infarction for 30-42 days | Double blind Parallel groups Sample size: 317/309 Primary endpoint: No primary outcome clearly defined FU duration: 2 y part of a 3-group trial | PARIS, 1980 | Aspirin (324 mg) 3x/d (n=810) vs. Placebo (n=406) | patients who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/406 Primary endpoint: No primary outcome clearly defined FU duration: 41 mo part of 3-group trial | JAMIS, 1999 | Aspirin (81 mg) 1x/d (n=250) vs. No antiplatelets (n=230) | patients with AMI within 1 month from the onset of symptoms | Open Parallel groups Sample size: 250/230 Primary endpoint: No primary outcome clearly defined FU duration: 1.3 y (mean) part of a 3-group trial |
|
post myocardial infarction | clopidogrel | not classified | versus aspirin No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
CAPRIE, 1996 | clopidogrel vs aspirin | | | |
Trial | Treatments | Patients | Method |
---|
CAPRIE, 1996 | Clopidogrel (75 mg) 1x/d for a minimum of one year and a maximum of 3 years (n=9599) vs. Aspirin (325 mg) 1x/d (n=9586) | patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease | Double blind Parallel groups Sample size: 9599/9586 Primary endpoint: ischaemic stroke, myocardial infarction, vascular death FU duration: 1.91 y |
|
post myocardial infarction | dipyridamol | not classified | versus placebo or control No demonstrated result for efficacy | 2 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
PARIS, 1980 | dipyridamol + aspirin vs placebo | | | Stroke 0.63 [0.25; 1.58] | PARIS-II, 1986 | dipyridamol + aspirin vs placebo | | | Stroke 0.61 [0.35; 1.05] |
Trial | Treatments | Patients | Method |
---|
PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810) vs. Placebo (n=406) | patients who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/406 Primary endpoint: No primary outcome clearly defined FU duration: 41 months (mean) part of 3-group trial | PARIS-II, 1986 | Aspirin (330 mg) + dipyridamole (75 mg) 3x/d (n=1563) vs. Placebo (n=1565) | patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously | Double blind Parallel groups Sample size: 1563/1565 Primary endpoint: No primary outcome clearly defined FU duration: 23.4 months |
|
post myocardial infarction | dipyridamol | not classified | versus aspirin No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
PARIS, 1980 | dipyridamol + aspirin vs aspirin | | | Death or nonfatal MI 1.05 [0.84; 1.30] |
Trial | Treatments | Patients | Method |
---|
PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d (n=810) vs. Aspirin (324 mg) 3x/d (n=810) | patuents who had recovered from myocardial infarction | Double blind Parallel groups Sample size: 810/810 Primary endpoint: No primary outcome clearly defined FU duration: 41 months part of 3-group trial |
|
post myocardial infarction | ticagrelor | secondary prevention | versus placebo or control No demonstrated result for efficacy ticagrelor inferior to placebo (on top aspirin) in terms of Major hemorrhage in PEGASUS 60mg, 2015 (secondary prevention patients) ticagrelor inferior to placebo (on top aspirin) in terms of Major hemorrhage in PEGASUS 90mg, 2015 (secondary prevention patients) | 2 trials | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
PEGASUS 60mg, 2015 | ticagrelor vs placebo (on top aspirin) | Stroke (any) 0.75 [0.57; 0.98] myocardial infarction 0.85 [0.73; 0.99] all vascular event 0.85 [0.75; 0.95] CV death, MI, stroke 0.85 [0.75; 0.95] | Major hemorrhage 2.16 [1.56; 2.99] | All cause mortality 0.89 [0.76; 1.04] death from CHD 0.81 [0.63; 1.04] cardiovascular death 0.83 [0.68; 1.01] fatal bleeding 0.92 [0.41; 2.08] Intracranial haemorrhage 1.10 [0.67; 1.81] | PEGASUS 90mg, 2015 | ticagrelor vs placebo (on top aspirin) | death from CHD 0.74 [0.57; 0.96] myocardial infarction 0.82 [0.70; 0.95] all vascular event 0.85 [0.76; 0.96] CV death, MI, stroke 0.85 [0.76; 0.96] | Major hemorrhage 2.36 [1.72; 3.24] | All cause mortality 1.00 [0.86; 1.16] cardiovascular death 0.87 [0.71; 1.06] fatal bleeding 0.50 [0.19; 1.33] Intracranial haemorrhage 1.26 [0.73; 2.18] Stroke (any) 0.82 [0.63; 1.07] |
Trial | Treatments | Patients | Method |
---|
PEGASUS 60mg, 2015 | ticagrelor at a dose of 60 mg twice daily (n=7045) vs. placebo (n=7067) | patients who had
had a myocardial infarction 1 to 3 years earlier | double-blind Parallel groups Sample size: 7045/7067 Primary endpoint: cardiovascular death, myocardial FU duration: 2.75 y (median) | PEGASUS 90mg, 2015 | ticagrelor at a dose of 90 mg twice daily
(n=7050) vs. (n=7067)
| patients who had
had a myocardial infarction 1 to 3 years earlier
| double-blind Sample size: 7050/7067 Primary endpoint: cardiovascular death, myocardial FU duration: 2.75 y (median)
|
|
post myocardial infarction | vorapaxar | secondary prevention | versus placebo or control No demonstrated result for efficacy vorapaxar inferior to placebo (on top aspirin) in terms of major haemorrhage requiring admission to hospital in TRA-2P TIMI 50, 2012 (secondary prevention patients) vorapaxar inferior to placebo (on top aspirin) in terms of Major hemorrhage in TRA-2P TIMI 50, 2012 (secondary prevention patients) vorapaxar inferior to placebo (on top aspirin) in terms of Intracranial haemorrhage in TRA-2P TIMI 50, 2012 (secondary prevention patients) | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
TRA-2P TIMI 50, 2012 | vorapaxar vs placebo (on top aspirin) | myocardial infarction 0.84 [0.75; 0.93] all vascular event 0.87 [0.80; 0.94] CV death, MI, stroke 0.87 [0.81; 0.95] | major haemorrhage requiring admission to hospital 1.42 [1.32; 1.52] Major hemorrhage 1.45 [1.21; 1.73] Intracranial haemorrhage 1.92 [1.38; 2.68] | All cause mortality 0.96 [0.85; 1.07] cardiovascular death 0.89 [0.76; 1.05] fatal bleeding 1.45 [0.82; 2.56] Stroke (any) 0.97 [0.83; 1.13] |
Trial | Treatments | Patients | Method |
---|
TRA-2P TIMI 50, 2012 | vorapaxar (SCH 530348) 2.5-mg daily (n=13225) vs. placebo (added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel) (n=13244) | patients with a known history of atherosclerosis (MI, ischemic stroke, or peripheral vascular disease) trial was discontinued in patients who experienced a stroke. The study drug will be continued in patients with previous MI or peripheral disease | double-blind Parallel groups Sample size: 13225/13244 Primary endpoint: CV death, MI, stroke, urgent revascularization FU duration: 2.5 y (median) |
|
post stroke | aspirin | not classified | versus placebo or control No demonstrated result for efficacy | 12 trials | meta-analysis | |